Press releases by members


21 September 2018
Barcelona Science Park celebrates 20 years as a scientific and business innovation centre Parc Científic de Barcelona (PCB)
Barcelona Science Park celebrates 20 years as a scientific and business innovation centre
Yesterday, Barcelona Science Park (Parc Científic de Barcelona, PCB) held the first of a number of events scheduled to commemorate its 20 years as a meeting place for universities, companies and society. Established by the University of Barcelona (UB) in 1997, was the first science park in Spain.
  View more
21 September 2018
BIOLAN reinforces its commitment to the Philippine market by participating in its National Tuna Congress BIOLAN MICROBIOSENSORES
BIOLAN reinforces its commitment to the Philippine market by participating in its National Tuna Congress On September 5, 6 and 7, took place in General Santos, Philippines, the National Tuna Congress in which BIOLAN participated accompanying collaborating companies and customers.
  View more
3 September 2018
BIOLAN has taken part in the AOAC 132nd Annual Meeting & Exposition at Toronto BIOLAN MICROBIOSENSORES
BIOLAN has taken part in the AOAC 132nd Annual Meeting & Exposition at Toronto The AOAC INTERNATIONAL, Association of Official Analytical Chemists, has celebrated its 132nd Annual Meeting & Exposition in Toronto (Canada), from 26 till 29 August, 2018, and BIOLAN, as AOAC International Affiliate member, has participated in this event presenting its own innovative analytical methods for food quality and safety.
  View more
27 August 2018
New Agriculture Project in Sierra Leone BIORIZON BIOTECH, S.L.
New Agriculture Project in Sierra Leone Spanish biotechnology company BiorizonBiotech is moving forward with the implementation of its Nueva Agricultura project, launched in September 2016 and aimed at the economic and social development of the community of Madina, in the northern district of Kambia, Sierra Leone. About 300 adults and about 70 children currently live in Madina. Everyone participates and benefits from this project.
  View more
30 July 2018
SOM Biotech initiates of Phase 2a clinical trial of SOM3355 in Huntington’s disease patients Parc Científic de Barcelona (PCB)
SOM Biotech initiates of Phase 2a clinical trial of SOM3355 in Huntington’s disease patients SOM Biotech, a clinical-stage biopharmaceutical company that discovers and develops drugs for orphan indications in the central nervous system, has initiated of Phase 2a clinical trial of its compound SOM3355 for the treatment of the chorea movements associated to Huntington’s disease. The investigational product is a repositioned drug, currently commercialized for the treatment of hypertension.
  View more
30 July 2018
OSASEN will present at the BIOSPAIN 2018 its last innovative biosensors for healthcare OSASEN SENSORES, S.L.
OSASEN will present at the BIOSPAIN 2018 its last innovative biosensors for healthcare OSASEN SENSORES belonging to the BIOLAN Group will participate actively at the BIOSPAIN 2018 Convention that will be held from September 25 to 27 in the city of Seville.
  View more
25 July 2018
Participation of BIOLAN and OSASEN at EuroScience Open Forum 2018 OSASEN SENSORES, S.L.
Participation of BIOLAN and OSASEN at EuroScience Open Forum 2018 The 8th EuroScience Open Forum (ESOF) edition has taken place in Toulouse (France), from 9 till 14 July, 2018, and the BIOLAN Group has participated in this event presenting its last technological advances.
  View more
25 July 2018
Maria Terrades, CEO of the Barcelona Science Park Parc Científic de Barcelona (PCB)
Maria Terrades, CEO of the Barcelona Science Park

The Barcelona Science Park (Parc Científic de Barcelona, PCB) Board of Trustees agreed to appoint Maria Terrades as the PCB’s General Director on 21 June. She moves into the post with the aim of consolidating the Park as one of the leading European clusters for research excellence, entrepreneurship and innovation in life sciences.
  View more
24 July 2018
medmesafe is one of the 100 finalists of the south summit medmesafe
medmesafe is one of the 100 finalists of the south summit medmesafe is the first online platform that offers genetic analysis services with video consulting.
Through the platform, anyone can know their genetic predisposition to develop certain diseases with a strong genetic component. Then, advised by a doctor, make preventive decisions that minimize the potential risk of develop diseases and improve their health.
  View more
24 July 2018
medmesafe launches a new genetic counselling service through online videoconsultation medmesafe
medmesafe launches a new genetic counselling service through online videoconsultation According to WHO, 20% of our health depends on our genes, so it is important to understand the role they play and the influence they have. In this sense, medmesafe has launched a new genetic counseling service directly available through the platform.
  View more
23 July 2018
Participation of BIOLAN and OSASEN at EuroScience Open Forum 2018 BIOLAN MICROBIOSENSORES
Participation of BIOLAN and OSASEN at EuroScience Open Forum 2018 The 8th EuroScience Open Forum (ESOF) edition has taken place in Toulouse (France), from 9 till 14 July, 2018, and the BIOLAN Group has participated in this event presenting its last technological advances.
  View more
18 July 2018
ilS, five years connecting companies with world experts in health sciences Parc Científic de Barcelona (PCB)
ilS, five years connecting companies with world experts in health sciences The consultancy firm Insights in Life Sciences (ilS), which is based at the Barcelona Science Park, is celebrating its fifth anniversary this year, with more than 100 projects under its belt, 40 clients and a network of 15,000 experts across the world.
  View more
27 June 2018
Almirall seeks new compounds to improve skin health Almirall, S.A.
Almirall seeks new compounds to improve skin health AlmirallShare new call aims at finding a use for existing advanced small molecules in the treatment of atopic dermatitis, psoriasis, actinic keratosis, acne, and related dermatological diseases
  View more
13 June 2018
BIORIZON BIOTECH, IN THE EUROPEAN RESEARCH AND APPLICATION ELITE ON MICRO-ALGAE BIORIZON BIOTECH, S.L.
BIORIZON BIOTECH, IN THE EUROPEAN RESEARCH AND APPLICATION ELITE ON MICRO-ALGAE The biotechnology-based company Biorizon Biotech from Almeria has joined as a full partner in the European Algae Biomass Association (EABA), based in Brussels, chaired by Vito Verdelho.
  View more
7 June 2018
XI Edición del Programa en “Desarrollo de Negocio y Licencias en la Industria Farmacéutica” de CESIF en Barcelona Centro de Estudios Superiores de la Industria Farmacéutica
XI Edición del Programa en “Desarrollo de Negocio y Licencias en la Industria Farmacéutica” de CESIF en Barcelona Curso de Introducción y Entrenamiento a la función de Desarrollo de Negocio y Licencias en las áreas de Éticos, Genéricos y Consumer Health.
  View more
21 May 2018
CESIF convoca la III Edición del Programa "Regulatory & Compliance: socios estratégicos en el Sector Salud" Centro de Estudios Superiores de la Industria Farmacéutica
CESIF convoca la III Edición del Programa La III Edición del Programa se realizará en la Sede de CESIF en Madrid, junto a Regulatory 3.0 y en colaboración con AEFI (Asociación Española de Farmacéuticos de la Industria).
  View more
21 May 2018
BIORIZON BIOTECH ENHANCES INVESTIGATION BIORIZON BIOTECH, S.L.
BIORIZON BIOTECH ENHANCES INVESTIGATION It is intended to optimize the obtaining procedure adjusting parameters and establishing quality controls in order to determine optimal operational conditions required to stabilize specific bacterial strain.
  View more
16 May 2018
Launching MedTeX, the accelerator for medical technology Parc Científic de Barcelona (PCB)
Launching MedTeX, the accelerator for medical technology The Barcelona Science Park, the Bosch i Gimpera Foundation and the Barcelona Entrepreneurship Institute are giving the go ahead for the MedTeX acceleration programme, a ground-breaking initiative —co-financed by ACCIÓ— to boost emerging enterprises with an innovative business project that shows a clear international commitment within the field of medical technologies and digital health.
  View more
14 May 2018
DTI Foundation: A decade promoting research and training in donation and transplant Parc Científic de Barcelona (PCB)
DTI Foundation: A decade promoting research and training in donation and transplant Yesterday, DTI Foundation celebrated its 10th anniversary at Barcelona Science Park. The Foundation —created in Barcelona in 2008— was conceived with the aim of providing consultancy, training and support to professionals in the area of organ, tissue and human cell donation and transplantation worldwide.
  View more
26 April 2018
BIOFISH 300 SULPHITE CERTIFIED AS AOAC® PTM, SECOND CERTIFICATION AOAC OBTAINED BY BIOLAN BIOLAN MICROBIOSENSORES
BIOFISH 300 SULPHITE CERTIFIED AS AOAC® PTM, SECOND CERTIFICATION AOAC OBTAINED BY BIOLAN BIOFISH 300 SUL has been certified as AOAC® Perfomance TestedSM by the AOAC Research Institute under license number 031802 for the determination of sulphites (measured as SO2) in raw and boiled shrimp.
  View more
25 April 2018
CESIF convoca la II Edición del Programa Superior en Market Access Centro de Estudios Superiores de la Industria Farmacéutica
CESIF convoca la II Edición del Programa Superior en Market Access Tras el éxito de la primera edición, el Centro de Estudios Superiores de la Industria Farmacéutica (CESIF) convoca una nueva edición del Programa Superior de Especialización en Market Access que se impartirá desde noviembre de 2018 en Madrid.
  View more
19 April 2018
GalChimia opens an R&D centre in the Barcelona Science Park Parc Científic de Barcelona (PCB)
GalChimia opens an R&D centre in the Barcelona Science Park Galician company GalChimia –a specialist in organic chemistry products and services for the pharmaceutical industry– has today opened its R&D centre in the Barcelona Science Park to step up its growth and internationalisation strategy.
  View more
4 April 2018
Vytrus finishes 1M capital round Vytrus Biotech - Phyture
Vytrus finishes 1M capital round Vytrus has succesfully finished its capital round, that started during the last trimester of 2017, obtaining new ressource, with the value of 1 million euros. This investment will allow the company to continue it's expansion strategy, including its future incorporation on a European secondary stock market.
  View more
23 March 2018
Excellent reception of the BIOFISH 300 in the presentation to the fishing sector and food safety authorities of Morocco BIOLAN MICROBIOSENSORES
Excellent reception of the BIOFISH 300 in the presentation to the fishing sector and food safety authorities of Morocco On February 8, BIOLAN, through its delegation in Morocco, organized a conference at the Kenzi Hotel in Casablanca (Morocco) to present the BIOLAN technology.
  View more
6 March 2018
Biorizon Biotech, the only at the IV International Biotechnology Symposium, held in Fez BIORIZON BIOTECH, S.L.
Biorizon Biotech, the only at the IV International Biotechnology Symposium, held in Fez The invitation of the Almeria Company was endorsed by the professor of the Engineering Department of the University of Almería and member of the Hassan II Academy of Sciences and Techniques of Morocco, the professor, and researcher El Hassan Belarbi Haftllaoui
  View more
15 February 2018
DSM to exclusively market BIOMILK 300, residual lactose analyser produced by BIOLAN, expanding availability for dairy producers worldwide BIOLAN MICROBIOSENSORES
DSM to exclusively market BIOMILK 300, residual lactose analyser produced by BIOLAN, expanding availability for dairy producers worldwide DSM, a global science-based company active in health, nutrition and materials will exclusively market BIOMILK 300.
  View more
24 January 2018
EIT Health Wild Card: €4 million in search of innovative health ideas Parc Científic de Barcelona (PCB)
EIT Health Wild Card: €4 million in search of innovative health ideas Within the framework of the Wild Card programme, EIT Health consortium –the largest European body for innovation in healthy living and active ageing– has announced €4 million in funding for disruptive initiatives that help transform European healthcare and mitigate the social and economic impact of the progressive ageing of the population.
  View more
21 January 2018
Lipopharma awarded a 6,15M€ grant by the H2020 Programme to conduct a PIIb trial with 2OHOA in patients with newly-diagnosed glioblastoma Lipopharma Therapeutics
The European Commission (EC) has awarded a 6,15M€ grant to develop the project CLINGLIO to a multinational consortium lead by Lipopharma and integrated by 12 leading clinical research institutions, Universities and SMEs from Europe, Israel and the USA. The objective of CLINGLIO is the execution of “A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma”. The duration of the CLINGLIO project is 36 months and the starting date is 1st of December, 2017
  View more
16 January 2018
CESIF convoca la V Ed. del Programa en Project Management en Investigación Clínica Centro de Estudios Superiores de la Industria Farmacéutica
CESIF convoca la V Ed. del Programa en Project Management en Investigación Clínica Avalada por anteriores ediciones, esta formación pionera y única está orientada a la obtención de la Certificación en PMP® (Project Management Professional) adaptado a la Investigación Clínica y alineado con el PMBOK® del PMI® 6 edición (septiembre de 2017).
  View more
16 January 2018
CESIF convoca la X Ed. del Programa en Desarrollo de Negocio y Licencias en la Industria Farmacéutica en Madrid Centro de Estudios Superiores de la Industria Farmacéutica
CESIF convoca la X Ed. del Programa en Desarrollo de Negocio y Licencias en la Industria Farmacéutica en Madrid Dirigido a profesionales de la Industria Farmacéutica y Biotecnológica, así como a Jefes de Unidades de Negocio, Country Managers y Directores de compañías de reciente creación, que buscan un aplicación inmediata de las herramientas utilizadas en Desarrollo de Negocio.
  View more
15 January 2018
Mind the Byte acquires Intelligent Pharma Parc Científic de Barcelona (PCB)
Mind the Byte acquires Intelligent Pharma Mind the Byte a pioneer in the development of technologies based on artificial intelligence, cloud and big data for computational drug design, has acquired 100% of Intelligent Pharma, one of the leaders in Spain in chemoinformatics services for the pharmaceutical and biotechnology industry.
  View more
9 January 2018
Biosearch S.A. signs a license agreement with Nestlé for its “Lactobacillus fermentum LC40 ®” strain. Biosearch S.A.
Biosearch S.A. signs a license agreement with Nestlé for its “Lactobacillus fermentum LC40 ®” strain. Biosearch, S.A., a leading biotechnical company in the world of healthy ingredients, has announced the signing of a license and supply agreement with Nestec S.A., a company of the Nestlé group, for the worldwide marketing of “Hereditum® Lactobacillus fermentum LC40®” in a food supplement aimed at breastfeeding women for the purpose of maintaining healthy lactation.
  View more
15 December 2017
IQS, EL ÚNICO CENTRO UNIVERSITARIO EN ESPAÑA CON LICENCIA NCF COMO LABORATORIO DE CONTROL DE CALIDAD IQS
IQS, EL ÚNICO CENTRO UNIVERSITARIO EN ESPAÑA CON LICENCIA NCF COMO LABORATORIO DE CONTROL DE CALIDAD El pasado 28 de septiembre, IQS recibía la comunicación favorable, por parte de la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), como laboratorio farmacéutico para realizar actividades de Control de Calidad (análisis físico-químicos) de principios activos, medicamentos y materias primas en general.
  View more
27 November 2017
Improvement of fertility in women with polycystic ovary syndrome. Biosearch Life's new clinical trial and patent. Biosearch S.A.
Improvement of fertility in women with polycystic ovary syndrome. Biosearch Life's new clinical trial and patent. Biosearch Life has applied for a patent based on a new method for increasing the rate of embryo implantation in polycystic ovary syndrome, as well as for the treatment of symptoms of the disease: Method for increasing embryo implantation rates in a female subject suffering polycystic ovary syndrome ".
  View more
7 November 2017
Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for bevantolol (Calvan®) SOM Biotech SL
Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for bevantolol (Calvan®) SOM Biotech has determined and validated an entirely new usage for Nippon Chemiphar’s marketed hypertension therapy bevantolol (Calvan®): Huntington's disease.
  View more
5 November 2017
DR Healthcare, global food producer for the DAO deficit DR HEALTHCARE, S.L.
DR Healthcare, global food producer for the DAO deficit The biomedical company has obtained 40 global patents on the deficiency of DAO and its associated pathologies during the last decade
  View more
26 October 2017
Embryotools successfully concludes the first trials on an innovative assisted reproduction technique Parc Científic de Barcelona (PCB)
Embryotools successfully concludes the first trials on an innovative assisted reproduction technique
Embryotools—headquartered at Barcelona Science Park (PCB)— has successfully concluded tests on animal models to validate an innovative assisted reproduction technique known as Maternal Spindle Transfer (MST). The project has developed in partnership with the PCB-PRBB Animal Facility Alliance and the company Reprogenetics UK
  View more
26 October 2017
medmesafe, a new ehealth genetic analysis platform, has been launched medmesafe
medmesafe, a new ehealth genetic analysis platform, has been launched A new eHealth platform for genetic analysis and video consultation for private patients, is finally online, backed by an internationally recognized Ethical Committee.
  View more
17 October 2017
Omakase Consulting - Opening new office in Madrid Omakase Consulting, S.L.
As a consequence of its continuous growth, Omakase Consulting announces the opening of an office in Madrid from which, in conjunction with its Barcelona office, will continue to offer our strategic consultancy services in the areas of Evidence Generation, Multicriteria Decision Analysis (MCDA) and Pricing & Market Access.
Follow us on LinkedIn for more news
  View more
25 September 2017
VIVEbiotech´s CEO in the media: Gurutz Linazasoro, contribute his opinion about the biotechnology sector in Basque Country VIVEbiotech

Different Biotechnology Companies have actively participated in extended report from the Diario Vasco daily newspaper.
  View more
20 September 2017
Microomics Systems S.L. Incorporation Microomics Systems S.L.
Microomics S.L. has been incorporated the 14th of september 2017 as a Biotech spin-off company of the CRG (Centre for Genomic Regulation) and the participation of ICREA (Catalan Institution for Research and Advanced Studies).
  View more
12 September 2017
Biosearch Life will be involved in the PREMIUM project, approved by European Commission Biosearch S.A.
Biosearch Life will be involved in the PREMIUM project, approved by European Commission The European Commission has recently announced the approval of the PREMIUM proposal: “Preservation of microorganisms by understanding the protective mechanisms of oligosaccharides”, submitted to the call: H2020-MSCA-RISE-2017.
  View more
11 September 2017
Sector Biofarmacéutico: Master Class CESIF Barcelona Centro de Estudios Superiores de la Industria Farmacéutica
Sector Biofarmacéutico: Master Class CESIF Barcelona El próximo día 20 de septiembre CESIF organiza en su sede de Barcelona una Master Class sobre el Sector Biofarmacéutico con la colaboración de ASBTEC (Asociación de Biotecnólogos de Cataluña).
  View more
2 August 2017
SOM Biotech licenses its first product and expands to the United States SOM Biotech SL
SOM Biotech licenses its first product and expands to the United States SOM Biotech has concluded a worldwide license agreement with Corino Therapeutics Inc. to clinically develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). The geographic expansion, and the clinical development of SOM’s most advanced assets, will be capitalized through the licensing revenues from SOM0226, as well as the commencing Series A fundraising.
  View more
24 July 2017
CESIF convoca el Programa Superior en Market Access Centro de Estudios Superiores de la Industria Farmacéutica
CESIF convoca el Programa Superior en Market Access El Programa aporta una visión global, multifuncional y completa sobre el Sector de la Salud que, en la actualidad, necesita Profesionales Expertos, conocedores de la realidad del Sistema Sanitario y de las herramientas necesarias para poder implementar Planes de Acceso eficaces.
  View more
13 July 2017
Life Sciences Newsletter nº4 Gómez-Acebo & Pombo Abogados, S. L. P.
At present, medical devices are regulated in the EU by three directives dating back to the 1990s: (a) Council Directive of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable medical devices (90/385/EEC), (b) Council Directive 93/42/EEC of 14 June 1993 concerning medical devices...
  View more
13 July 2017
IDEN BIOTECHNOLOGY’S COMMITMENT FOR THE BIOTECHNOLOGY APPROACH TO SOCIETY Iden Biotechnology
IDEN BIOTECHNOLOGY’S COMMITMENT FOR THE BIOTECHNOLOGY APPROACH TO SOCIETY With the goal of approaching the biotechnology and its contribution in the agriculture to the society, along this year, Iden Biotechnology is carrying out different informative actions.
  View more
13 July 2017
CESIF convoca su primer Programa Superior en Digital Healthcare Business Centro de Estudios Superiores de la Industria Farmacéutica
CESIF convoca su primer Programa Superior en Digital Healthcare Business El Programa Superior en Digital Healthcare Business ha sido diseñado ad hoc para el Profesional de la Salud que desee especializarse en las nuevas formas de Marketing Digital aplicadas al entorno sanitario.
  View more
12 July 2017
CESIF convoca la IX Edición del PAE en "Desarrollo de Negocio y Licencias en la Industria Farmacéutica" en Barcelona Centro de Estudios Superiores de la Industria Farmacéutica
CESIF convoca la IX Edición del PAE en Tras el éxito de las ocho ediciones anteriores, el Centro de Estudios Superiores de la Industria Farmacéutica (CESIF) convoca en Barcelona este Programa Abierto de Especialización en “Desarrollo de Negocio y Licencias en la Industria Farmacéutica”.
  View more
11 July 2017
CESIF convoca la IV Edición del Programa Abierto de Especialización en "Project Management en Investigación Clínica" Centro de Estudios Superiores de la Industria Farmacéutica
CESIF convoca la IV Edición del Programa Abierto de Especialización en El Programa, consolidado por anteriores ediciones, está dirigido a profesionales vinculados al ámbito de la Investigación Clínica, tanto en Laboratorios Farmacéuticos, CROs, como Centros de Investigación con el fin de formarse para obtener la Certificación PMP®.
  View more
2 June 2017
Launching of KeTLOD Project Knowledge Transfer in Organ Donation from Europe to China Parc Científic de Barcelona (PCB)
Launching of KeTLOD Project Knowledge Transfer in Organ Donation from Europe to China The University of Barcelona (UB) and the DTI Foundation, located at the Barcelona Science Park (PCB), are the main coordinators of the European project KeTLOD, an initiative of the European Union that aim to design the first postgraduate program in organ donation in China and to implement it in seven universities all over the country.
  View more
24 May 2017
SOM Biotech announces a worldwide license with Corino Therapeutics, Inc. for SOM0226, a drug for the treatment of TTR Amyloidosis. SOM Biotech SL
SOM Biotech announces a worldwide license with Corino Therapeutics, Inc. for SOM0226, a drug for the treatment of TTR Amyloidosis. SOM Biotech Ltd a leading clinical-stage biopharmaceutical company specialized in drug repurposing to treat rare diseases with a focus on CNS diseases, today announces an exclusive worldwide license agreement with U.S. based Corino Therapeutics, Inc. (Corino), for the clinical development and commercialization of SOM0226 (CRX-1008), a drug for the treatment of ATTR.
  View more
19 May 2017
Centro de Estudios Superiores de la Industria Farmacéutica
CESIF convoca la Máster Class enfocada en las salidas profesionales en la Industria Alimentaria el próximo día 7 de Junio en Barcelona
  View more
17 May 2017
Centro de Estudios Superiores de la Industria Farmacéutica
Jornada de Bioemprendedores enfocada en "El elefante Rosa"
  View more
4 May 2017
Los nuevos reglamentos de la Unión Europea sobre productos sanitarios Gómez-Acebo & Pombo Abogados, S. L. P.
Los nuevos reglamentos de la Unión Europea sobre productos sanitariosEn este documento se exponen los principales rasgos de los dos nuevos reglamentos de la Unión Europea sobre productos sanitarios, ya aprobados y pendientes de publicación en el Diario Oficial.
  View more
3 May 2017
Opening ceremony of the 15th edition of the Live Research Fair, Parc Científic de Barcelona (PCB)
Opening ceremony of the 15th edition of the Live Research Fair, Getting society closer to science, creating scientific vocation and making interaction easier between the audience and scientists are the main goals of the 15th edition of the Live Research Fair, which will take place in CosmoCaixa Barcelona from the 3rd to the 6th of May.
  View more
25 April 2017
Bionaturis out-licenses its Leishmaniasis vaccine for Argentina and Paraguay BIONATURIS GROUP
Bionaturis has signed an exclusive development, manufacturing, registration, and commercialization license of its Leishmaniasis vaccine with the company Biotandil for Argentina and Paraguay
According to the terms of the license, Bionaturis will receive 50% of the profits resulting of the commercialization.
  View more
20 April 2017
Life Sciences Newsletter nº3 Gómez-Acebo & Pombo Abogados, S. L. P.
As scientific evidence is insufficient to establish a cause and effect relationship between the consumption of Anxiofit-1 and the reduction of subthreshold and mild anxiety, Commission Regulation (EU) 2017/236 of 10 February 2017 refusing to authorise a health claim made on foods and referring to the reduction of disease risk refuses to...
  View more
29 March 2017
BIOKIT licenses CRISBIO™ technology to make high quality recombinant proteins for in vitro diagnostics for human use. ALGENEX (Alternative Gene Expression S.L.)
BIOKIT licenses CRISBIO™ technology to make high quality recombinant proteins for in vitro diagnostics for human use. BIOKIT and ALGENEX are extending their non-exclusive, commercial license agreement, to include also the CRISBIO™ technology for the manufacturing of recombinant proteins.
  View more
2 March 2017
Life Sciences Newsletter nº2 Gómez-Acebo & Pombo Abogados, S. L. P.
Published in OJ L 317, 23/11/2016, this Regulation establishes rules to determine the phytosanitary risks posed by any species, strain or biotype of pathogenic agents, animals or parasitic plants injurious to plants or plant products (‘pests’) and measures to reduce those risks to an acceptable level...
  View more
17 February 2017
Esteve and Enzymlogic join together to drive GPCR drug discovery Enzymlogic
Esteve and Enzymlogic join together to drive GPCR drug discovery Enzymlogic has entered into a research collaboration agreement with Esteve whereby Enzymlogic will direct its novel Binding Kinetics Platform to characterize selected compounds against mu-Opioid receptor.
  View more
1 February 2017
Atrys Health and HM Hospital made an agreement to work on diagnostic kit ATRYS
Atrys Health and HM Hospital made an agreement to work on diagnostic kit The aim of the proyect is the development of a diagnostic kit for the implementation of a correct treatment on brain tumor, through liquid byopsy.
  View more
26 January 2017
SOM Biotech closes a €2M financing round SOM Biotech SL
SOM Biotech closes a €2M financing round SOM Biotech –a clinical-stage pharmaceutical company specialized in drug repositioning to treat rare diseases of the nervous system - has just closed a €2M financing round. The company will allocate this capital to boost its activities of internalization, co-development and licensing, as well as to finance a Ph2 of a drug for Huntington's, the 2nd asset of the company that reaches clinical stages.
  View more
12 January 2017
Sequentia launches AIR, a platform revolutionizing transcriptomics Parc Científic de Barcelona (PCB)
Sequentia launches AIR, a platform revolutionizing transcriptomics
Sequentia Biotech, based at the Barcelona Science Park, has launched a cloud computing platform called A.I.R. (Artificial Intelligence RNAseq), the first predictive bioinformatics tool that automatically analyzes mass transcriptomic data from the genome of any species, generated by the next generation sequencing technologies, providing a complete report in less than 24 hours.
  View more
23 December 2016
- ProtoQSAR
-
  View more
22 December 2016
The EUDONORGAN project for increasing organ donation in the European Union and neighbouring countries has been launched Parc Científic de Barcelona (PCB)
The EUDONORGAN project for increasing organ donation in the European Union and neighbouring countries has been launched The main objective of the European project EUDONORGAN is to provide training and increase social awareness in the EU and neighbouring countries with the ultimate aim to increase the number of donors. The project is led by the University of Barcelona - Bosch i Gimpera Foundation (UB-FBG) together with the DTI Foundation located at the Barcelona Science Park.
  View more
21 December 2016
Arian Internacional succesfully starts a consultancy división for European projects Parc Científic de Barcelona (PCB)
Arian Internacional succesfully starts a consultancy división for European projects Backed up by 14 years experience and more tan 200 companies advised on international projects, Arian Internacional–an associate company at the Barcelona Science Park (PCB) – has successfully started the European Projects Advisory/Consultancy service with the preparation of the ZeClinics– that has won € 1.87 million grant from the SME Instrument Phase 2.
  View more
20 December 2016
Aromics launches a crowdfunding campaign to accelerate the development of a drug for for mesothelioma treatment Parc Científic de Barcelona (PCB)
Aromics launches a crowdfunding campaign to accelerate the development of a drug for for mesothelioma treatment The biotech company Aromics, located at the Barcelona Science Park (PCB), has launched an equity crowdfunding campaign through the European platform CapitalCell, with the goal of raising a capital round up to 300,000€ for completing the preclinical package of its compound NAX035 for the treatment of asbestos-related cancer.
  View more
14 December 2016
Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer Ability Pharmaceuticals, SL
Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced today that has received orphan-drug designation (ODD) for ABTL0812 from the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer.
  View more
14 December 2016
Bionaturis strengthens actions for reducing the use of antibiotics in porcine industry BIONATURIS GROUP
Bionaturis strengthens actions for reducing the use of antibiotics in porcine industry The biotechnological company takes part in the PROVACIN consortium, joined by partners Piensos Jimenez –leaders of the project- and Iberico Comercializacion (IBERCOM), with the main goal of reducing the use of antibiotics in white and iberian pigs
  View more
10 December 2016
ZeClinics receives €1.87M funding from the Horizon 2020 SME Instrument Phase 2 ZeClinics
ZeClinics receives €1.87M funding from the Horizon 2020 SME Instrument Phase 2 ZeClinics has been granted with the SME Instrument Phase 2 within the European Union framework Horizon 2020, category "Supporting Innovative SMEs in the healthcare biotechnology sector". The company, mono-beneficiary, receives € 1.87 million, 100% of the proposed budget for the project "ZeCardio: High-throughput cardiotoxicity screening (HTS) with zebrafish embryo".
  View more
22 November 2016
Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients Ability Pharmaceuticals, SL
· ABTL0812 is administered in combination with carboplatin and paclitaxel
· Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona)lead the study, which includes other centers in Spain and France
  View more
16 November 2016
Enzymlogic, winner at Entrepreneur XXI Awards Enzymlogic
Enzymlogic, winner at Entrepreneur XXI Awards one of the three finalist in the Life Science category at the prestigious Entrepreneur XXI Awards ceremony.
  View more
15 November 2016
Custom PCR Master Mixes Ship in 10 Days with New Promega cGMP PCR Kit for Rapid Assay Development Promega Biotech Ibérica S.L.
Now available, the Promega PCR Optimization Kit allows customers to rapidly define their own unique PCR master mix manufactured under cGMP for research or clinical use. The user’s defined optimal solution may then be ordered from Promega at any time with a unique part number as a custom cGMP master mix for shipment within ten business days.
  View more
8 November 2016
Iproteos closes a round of funding valued at 1.5 millon Euros Parc Científic de Barcelona (PCB)
Iproteos closes a round of funding valued at 1.5 millon Euros Iproteos – based at the Barcelona Science Park– has closed a round of funding valued at 1.5 millon Euros, led by Caixa Capital Risc and with participation of Kinled Holding, a Hong Kong based investment company with offices in London, New York and Zurich, and the biotech ASCIL Biopharm.
  View more
3 November 2016
Gaia, the first intuitive SaaS software for human, animal & plant metagenomics that compares samples in real time Parc Científic de Barcelona (PCB)
Gaia, the first intuitive SaaS software for human, animal & plant metagenomics that compares samples in real time Sequentia Biotech based at the Barcelona Science Park (PCB) recently developed Gaia, an online bioinformatics tool able to manage and analyze metagenomic data from any microbial community (bacteria, viruses and eukaryotes) generated by new sequencing technologies (Next Generation Sequencing, NGS) applied to human, animal and plant genetics.
  View more
2 November 2016
Life Sciences Newsletter nº1 Gómez-Acebo & Pombo Abogados, S. L. P.
Este real decreto —publicado en el Boletín Oficial del Estado núm. 161, de 5 de julio del 2016— tiene por objeto establecer los requisitos y la regulación del procedimiento para la acreditación de institutos de investigación biomédica o sanitaria en el ámbito del Sistema Nacional de Salud de acuerdo con lo dispuesto por el artículo 88 de la Ley 14/2007, de 3 de julio, de Investigación Biomédica...
  View more
27 October 2016
Alcalá de Guadaíra will have the first Spanish laboratory technology microspheres BEST MEDICAL DIET
The delegate of Economic Development of the City of Alcalá de Guadaíra, Miriam Burgos, visited the facilities of Grupo Nueva Dietetic entity that created the first laboratory in Spain and second in the world with technology microspheres within the current expansion project is developing and that has led him to expand its facilities alcalareñas 1,400 square meters.

  View more
24 October 2016
GROWING RICE IN SIERRA LEONE BIORIZON BIOTECH, S.L.
GROWING RICE IN SIERRA LEONE 40.000 people from Sierra Leona would benefit from the Spanish company Biorizon Biotech to grow rice for the local population as a social project.
  View more
18 October 2016
PlantResponse Wins First Green Biotech Award from EuropaBio PlantResponse Biotech S.L.
PlantResponse Wins First Green Biotech Award from EuropaBio PlantResponse is the Most Innovative European Biotechnology SME in 2016. The Madrid-based biotech company was awarded first place in the agricultural/green biotech category at the 2016 EuropaBio Awards, which took place in Brussels on September 27.
  View more
6 October 2016
Our drug discovery platform win the Start Tel Aviv Competition Enzymlogic
Our drug discovery platform win the Start Tel Aviv Competition Binding kinetics platform participated as a finalist in the Health category of South Summit Startup Competition.
  View more
29 September 2016
Registration open: Master in Manufacturing of Advanced Therapy Medicinal Products FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD
Registration open: Master in Manufacturing of Advanced Therapy Medicinal Products The Andalusian Initiative in Advanced Therapies set up this Master in 2009. This degree will provide participants with the knowledge, skills and hands-on technical expertise necessary to face the challenges of manufacturing ATMPs for clinical use.
  View more
21 September 2016
Inveready leads a €3.5 Million round in Leukos Biotech Antares Consulting
The principal Investigator Ruth M. Risueño will lead the development of a new class of drugs against Leukemia Stem Cells.
  View more
12 September 2016
High Quality Sample Prep for Food Testing Promega Biotech Ibérica S.L.
High Quality Sample Prep for Food Testing Maxwell® RSC PureFood GMO* and Authentication Kit for food testing delivers automated high quality sample prep for food testing labs.
  View more
31 August 2016
The Biotechnology Business Institute expands its masters programs in business management applied to biomedicine and healthcare biotechnology Biotechnology Business Institute
The Biotechnology Business Institute –based at the Barcelona Science Park (PCB)– offers two new masters applied to the biotechnology and pharmaceutical industry sectors for the 2016-2017 academic year: the Master in Business Management and the Master in Marketing Management, in addition to the Master in Project Management, which is now in its third edition.
  View more
30 August 2016
Iden Biotechnology wins the CommBeBiz Award 2016 Iden Biotechnology
The CommBeBiz projects consortium (http://www.commbebiz.eu/) awards the innovation potential of Iden Biotechnology in bioeconomy research. Once a year, CommBeBiz awards the most exciting developments in bioeconomy research with a coaching prize – the CommBeBiz Business Awards (www.commbebiz.eu/awards )
  View more
29 August 2016
Our drug discovery platform win the Start Tel Aviv Competition Enzymlogic
Our drug discovery platform win the Start Tel Aviv Competition Enzymlogic is heading to Israel in September to represent Spain in one of the most incredible start-up economies in the world.
  View more
9 August 2016
Finance support BIORIZON BIOTECH, S.L.
Finance support Almeria company Biorizon Biotech has just received financial support from Spanish government to increase researching programs on micro algae.
  View more
26 July 2016
The loss of autonomy and pain, the issues of concern to our grandparents Sanofi Genzyme
The loss of autonomy and pain, the issues of concern to our grandparents
  View more
12 July 2016
Revolution, the scope of rotavirus beyond gastrointestinal infection Sanofi Genzyme
Revolution, the scope of rotavirus beyond gastrointestinal infection
  View more
6 July 2016
Enzymlogic named Best Tech Startup 2016 Enzymlogic
Enzymlogic named Best Tech Startup 2016 Last week, Enzymlogic was honored with the Best Tech Startup Award, which recognizes technological companies that address important issues for society, put innovation at the heart of their business strategy and have demonstrated high-growth potential.
  View more
29 June 2016
Registration in China has been granted for L. fermentum CECT5716 LC40, for infant formula milk. Biosearch S.A.
Registration in China has been granted for L. fermentum CECT5716 LC40, for infant formula milk. Biosearch Life, a biotechnology company focused on providing innovative solutions worldwide, has received authorization for registration of their probiotic strain Lactobacillus fermentum CECT5716 LC40, from the Family Planning and National Health Commission of the People's Republic of China. This registration, granted after a long and arduous process, allows the inclusion of LC40 in infant formula milk manufactured in China.
  View more
29 June 2016
ASCO sets its recommendations to increase prevention against HPV Sanofi Genzyme
ASCO sets its recommendations to increase prevention against HPV
  View more
27 June 2016
Vaccination, hygiene and dietary measures and reducing the consumption of snuff and alcohol, main strategies to prevent adult diseases Sanofi Genzyme
Vaccination, hygiene and dietary measures and reducing the consumption of snuff and alcohol, main strategies to prevent
adult diseases
  View more
21 June 2016
Experts call for increased awareness on the prevention of infectious diseases in adulthood Sanofi Genzyme
Experts call for increased awareness on the prevention of infectious diseases in adulthood
  View more
2 June 2016
Myriad myRisk Hereditary Cancer - APP Myriad Genetics España, S.L.U
Myriad myRisk Hereditary Cancer - APP A resource that provides a comprehensive
overview on clinical information associated
with Myriad’s myRisk Hereditary Cancer Panel.
  View more
31 May 2016
I Encuentro TeiBio Barcelona Biotechnology Business Institute
Gran acogida del primer encuentro para el emprendimiento científico en Barcelona.
  View more
31 May 2016
93% of parents with children up to 14 years say they are in favor of the prevention of infectious diseases Sanofi Genzyme
93% of parents with children up to 14 years say they are in favor of the prevention of infectious diseases
  View more
26 May 2016
Cases of Cervical Cancer could be reduced by 82% in Spain Sanofi Genzyme
Cases of Cervical Cancer could be reduced by 82% in Spain
  View more
23 May 2016
Protection from HPV vaccine reduces the risk of precancerous lesions Cervical Sanofi Genzyme
Protection from HPV vaccine reduces the risk of precancerous lesions Cervical
  View more
17 May 2016
Era7 Bionformatics’ CEO, was at the Launching of The National Microbiome Initiative event at The White House Era7 Information Technologies
Era7 Bionformatics’ CEO, was at the Launching of The National Microbiome Initiative event at The White House The White House Office of Science and Technology Policy (OSTP), in collaboration with Federal agencies and private-sector stakeholders, announced a new important initiative, The National Microbiome Initiative (NMI).
  View more
11 May 2016
Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. Ability Pharmaceuticals, SL
Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. • Collaboration Boosts Development of a Fully Differentiated Inhibitor of the PI3K/Akt/mTOR pathway.
• ABTL0812 is currently in Phase 2 Clinical Trials to Treat Lung and Endometrial Cancers.
  View more
10 May 2016
Enzymlogic granted with NEOTEC funding Enzymlogic
Enzymlogic granted with NEOTEC funding Technology-based company Enzymlogic has been granted with NEOTEC funding by the Ministry of Economy and Competitiveness through its Industrial Technological Development Centre (CDTI).
  View more
10 May 2016
El Herpes Zoster causes intense and disabling un dolor that deja as sequels miedo y vulnerability Sanofi Genzyme
El Herpes Zoster causes intense and disabling un dolor that deja as sequels miedo y vulnerability
  View more
3 May 2016
Bionaturis Group grows through the acquisition of the company ZIP Solutions BIONATURIS GROUP
Zera Intein Protein Solutions (ZIP) is specialized in the development of technologies for the production of peptides and recombinant proteins
Previous to the acquisition, ZIP and a multinational company signed a co-development and a worldwide exclusive license for Splittera®
  View more
21 April 2016
During the 3 months after suffering a HZ increases the risk of stroke or myocardial infarction Sanofi Genzyme
During the 3 months after suffering a HZ increases the risk of stroke or myocardial infarction
  View more
19 April 2016
Biosearch Life leads a FEDER INNTERCONECTA project focused on the health of women and children Biosearch S.A.
Biosearch Life leads a FEDER INNTERCONECTA project focused on the health of women and children Biosearch Life, in collaboration with two more Spanish companies in the biotechnology sector and Spanish food industry, have launched an R & D project in the development of new food products and nutritional supplements, based on natural ingredients, which help to prevent and treat certain health problems affecting women and children.
  View more
15 April 2016
Enzymlogic receives the seal of innovative SME Enzymlogic
Enzymlogic receives the seal of innovative SME The award identifies companies that have proven their innovative spirit in recent years and acknowledges the critical role of excellent science and industrial leadership play in solving societal challenges.
  View more
15 April 2016
The CCU could meet the biological factors necessary for its eradication in the future Sanofi Genzyme
The CCU could meet the biological factors necessary for its eradication in the future
  View more
13 April 2016
Kala Pharmaceuticals Announces Closing of $68 Million Series C Financing Ysios Capital Partners SGEIC, S.A
Kala Pharmaceuticals Announces Closing of $68 Million Series C Financing Secures financing needed to complete registration trials for KPI-121
  View more
7 April 2016
Biorizon holds International micro alge meeting BIORIZON BIOTECH, S.L.
Biorizon holds International micro alge meeting Nineteen international operators of the auxiliary industry Agriculture participated Wednesday in a briefing with BiorizonBiotech in the experimental center Las Palmerillas in El Ejido, Almería.
  View more
30 March 2016
AQUILÓN PRESENTS THE POSTER "PIGLIFE AQ1202: TESTING EFFICACY IN COMMERCIAL FARMS" Aquilón cyl, S.L
AQUILÓN PRESENTS THE POSTER Aquilón presents the poster "PigLife AQ1202: Testing efficacy in commercial farms" in the congress VII workshop of probiotics, prebiotics and health of the SEPYP.
  View more
28 March 2016
BIORIZON BIOTECH, S.L.
Spanish Biotechnological Company identifies natural bacteria as a soil fertility enhancer
  View more
18 March 2016
An adequate system of vaccination and screening is necessary to improve the prevention of Cervical Cancer in Spain Sanofi Genzyme
An adequate system of vaccination and screening is necessary to improve the prevention of Cervical Cancer in Spain
  View more
17 March 2016
3P Biopharmaceuticals named one of the best companies in Navarra over the last decade 3P Biopharmaceuticals, S.L.
3P Biopharmaceuticals named one of the best companies in Navarra over the last decade 3P Biopharmaceuticals has been named as one as the best companies in Navarra over the last decade
  View more
17 March 2016
ONCOGENICS WITH HONORS DREAMgenics, S.L.
ONCOgenics has achieved the highest score in the program of external quality control "Oncogene panel testing" offered by the European Molecular Genetics Quality Network (EMQN).
  View more
8 March 2016
New method to measure target engagement and drug residence Promega Biotech Ibérica S.L.
The therapeutic action of drugs is predicated on their physical engagement with cellular targets. Here we describe a broadly applicable method using bioluminescence resonance energy transfer (BRET) to reveal the binding characteristics of a drug with selected targets within intact cells
  View more
8 March 2016
”la Caixa” leads an investment round in Inbiomotion with the participation of Ysios Capital Ysios Capital Partners SGEIC, S.A
”la Caixa” leads an investment round in Inbiomotion with the participation of Ysios Capital The company concludes a 2.2 million Euro round led by ”la Caixa” through Caixa Capital Risc. Also participating in the operation were Ysios Capital, which led the first investment round for the company in 2012, and Fundación Vila Casas, which were already shareholders in the spin-off.
  View more
26 February 2016
Gardasil 9® receives CHMP Positive Opinion in Europe for management in a two-dose schedule Sanofi Genzyme

Sanofi Pasteur MSD announced that Gardasil 9® , its new nine-valent vaccine against human papillomavirus (HPV ) , has received a positive opinion from the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) for administration in a two-dose schedule in boys and girls between 9 and 14 years old.
  View more
24 February 2016
RESEARCHERS FISABIO show that diabetes, COPD and heart failure are risk factors for shingles KEY WITH AGE Sanofi Genzyme
RESEARCHERS FISABIO show that diabetes, COPD and heart failure are risk factors for shingles KEY WITH AGE RESEARCHERS FISABIO show that diabetes, COPD and heart failure are risk factors for shingles KEY WITH AGE
  View more
23 February 2016
New publication: NGS experiments show a correlation between EGFR2 upregulation and recovery from Guillain-Barré Syndrome. Era7 Information Technologies
Results from a recent publication made with the participation of Era7 Bioinformatics provide the first evidence for the implication of Early Growth Response Gene-2 (EGR2) in the development and outcome of Guillain-Barré Syndrome (GBS).
  View more
22 February 2016
Biosearch Life is leading the project METASIN Biosearch S.A.
Biosearch Life is leading the project METASIN The METASIN project’s main goal is to investigate and develop active ingredients, food and multifunctional food supplements capable of having an influence over the diseases and risk factors associated with metabolic syndrome.
  View more
22 February 2016
European experts propose initiatives aimed at establishing adult vaccination as the primary prevention Sanofi Genzyme
During the first biennial meeting of the World Association of infectious diseases and immunological disorders ( WAidid for its acronym in English ) , held in Milan from 18 to 20 February , they were presented the conclusions of the review of the posters carried by a group European experts in collaboration with Sanofi Pasteur MSD
  View more
21 February 2016
Biotech Aromics obtains the seal ‘Innovative SME’ Parc Científic de Barcelona (PCB)
Biotech Aromics obtains the seal ‘Innovative SME’ The Ministry of Economy and Competitiveness recently awarded the biotech Aromics the seal of ‘Innovative SME'. The company -founded in 2005 and specialized in the application of omic sciences in the research and development of new drugs and diagnostic methods- was part of the first generation of companies that participated in the Bioincubator project at the Barcelona Science Park (PCB).
  View more
21 February 2016
GreeNC, the first database of non-coding RNAs in plants Parc Científic de Barcelona (PCB)
GreeNC, the first database of non-coding RNAs in plants Sequentia Biotech, a company based at the Barcelona Science Park (PCB), has developed the first database of non-coding RNAs in vegetal species: GreeNC.
  View more
18 February 2016
health professionals advocate the importance of working on improving protection throughout all stages of life Sanofi Genzyme
Distinguished experts in Preventive Medicine , Pediatric and Infectious Diseases in Spain have met in Madrid in the XXIV International Conference on Vaccine Update , a meeting organized by the Department of Preventive Medicine of the University Hospital 12 de Octubre.
  View more
17 February 2016
Chickenpox , one of the viruses most concerns and doubts generated among parents finally can be prevented Sanofi Genzyme
Chickenpox , one of the viruses most concerns and doubts generated among parents finally can be prevented
The front of the varicella vaccine is one that most concerns and doubts generated among parents, so say 64 % of people who participated in the survey conducted by the community 2.0 Madresfera
  View more
11 February 2016
High vaccination rates in Navarra put the brakes on the movement of varicella Sanofi Genzyme
In the frame of the XII Vaccine Update Seminar to be held on 11 and 12 February , doctors and experts in the area will meet in Pamplona to discuss and demonstrate the latest developments in the area of vaccination .
  View more
8 February 2016
The vaccine against HPV reduces more than 90 % risk of developing genital warts in women at high risk Sanofi Genzyme
On 14 February, the World Day against Sexual Transmitted Infections ( STI ) , a date to be established with the aim to remind people the importance of preventing STIs and maintaining responsible sexual relationships.
  View more
2 February 2016
Myriad Genetics launches a 25-gene hereditary cancer panel Myriad Genetics España, S.L.U
Myriad Genetics launches a 25-gene hereditary cancer panel The test, called myRisk Hereditary Cancer, is the company's first to use a next-generation sequencing platform, primarily Illumina's HiSeq 2500.
  View more
29 January 2016
One in four Andalusian known that HPV affects both men and women Sanofi Genzyme
One in four Andalusian known that HPV affects both men and women One in four Andalusian known that HPV affects both men and women
  View more
29 January 2016
One in four Andalusian known that HPV affects both men and women Sanofi Genzyme
One in four Andalusian known that HPV affects both men and women One in four Andalusian known that HPV affects both men and women
  View more
29 January 2016
One in four Andalusian known that HPV affects both men and women Sanofi Genzyme
One in four Andalusian known that HPV affects both men and women One in four Andalusian known that HPV affects both men and women
  View more
29 January 2016
One in four Andalusian known that HPV affects both men and women Sanofi Genzyme
One in four Andalusian known that HPV affects both men and women One in four Andalusian known that HPV affects both men and women
  View more
29 January 2016
One in four Andalusian known that HPV affects both men and women Sanofi Genzyme
One in four Andalusian known that HPV affects both men and women One in four Andalusian known that HPV affects both men and women
  View more
29 January 2016
One in four Andalusian known that HPV affects both men and women Sanofi Genzyme
One in four Andalusian known that HPV affects both men and women One in four Andalusian known that HPV affects both men and women
  View more
27 January 2016
Experts call for vaccination schedule in adults in the National Health System Sanofi Genzyme
Experts call for vaccination schedule in adults in the National Health System Experts call for vaccination schedule in adults in the National Health System
  View more
25 January 2016
Biobide signs a contract with the U.S. National Institute of Environmental Health Sciences (NIH-NIEHS) BIONATURIS GROUP
This project will analyze the toxicological impact of exposure to 30 chemical compounds using zebrafish as animal model.
The NIEHS is one of the 27 Institutes and Centers composing the US-National Institutes of Health.
  View more
25 January 2016
The European Code Against Cancer recognizes the HPV vaccine as an effective preventive measure against cervical cancer Sanofi Genzyme

The fourth edition of the European Code Against Cancer includes 12 key recommendations to reduce the risk of cancer in general , and some types of cancer, in particular , such as cervical cancer ( CCU) , breast or colon.
  View more
14 January 2016
European patent granted to Biosearch Life for the use of probiotics for the treatment of mastitis Biosearch S.A.
European patent granted to Biosearch Life for the use of probiotics for the treatment of mastitis BiosearchLife, Biotechnology Company, focused on providing innovative solutions at global level, has been granted the European Patent nº EP2162143 “Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis”, published by the European Patents Office (EPO) in its newsletter last September and recently validated in twenty one countries.
  View more
12 January 2016
Bionaturis Group takes part in the development of a vaccine against cervical cancer BIONATURIS GROUP
The Centre for the Development of Industrial Technology (CDTI, in Spanish) has granted an incentive of 184.847,40 Euros to the company from the European Programme Eurostars
The project is led by the German company BioEnergy GmbH & Consultant with participation from the German Cancer Research Center
  View more
12 January 2016
Bionaturis Group takes part in the BIOMAP project BIONATURIS GROUP
BIOMAP is a consortium led by Laboratories Rovy that includes Vivacell Biotechnology Spain, Vaxdyn, and Bionaturis
The Feder-Interconecta Programme, via the Centre for the Development of Industrial Technology (CDTI, in Spanish), has granted Bionaturis 572.988€ for this biomedicine development initiative.
  View more
11 January 2016
Aelix Therapeutics completes Series A funding of €11.5M ($12.7M) for therapeutic HIV vaccine Ysios Capital Partners SGEIC, S.A
Aelix Therapeutics completes Series A funding of €11.5M ($12.7M) for therapeutic HIV vaccine Funds will support proof of concept studies for lead candidate HTI immunogen as a therapeutic vaccine against HIV infection
  View more
11 January 2016
Ignasi Belda: "We are the only service provider in computational chemistry with a presence in five countries" Parc Científic de Barcelona (PCB)
Ignasi Belda: Intelligent Pharma recently opened a new office in Munich (Germany). It is the fifth international office that the company has set up in the same number of years. The company also recently received a capital injection of 550,000 euros from the Avanza 2 program from the Spanish Ministry of Industry, Energy and Tourism, and the Torres Quevedo call from the Ministry of Economy and Competitiveness.
  View more
15 December 2015
3P Biopharmaceuticals, S.L.
3PBiopharmaceuticals recibe el Premio a la Innovación 2015 por la Cámara Navarra de Comercio e Industria. Este galardón reconoce la fuerte apuesta de la compañía navarra por mantenerse a la vanguardia de la innovación biofarmacéutica
  View more
10 December 2015
SOM Biotech is launching an Indiegogo Crowdfunding Campaign for Pediatric Rare Diseases SOM Biotech SL
SOM Biotech is launching an Indiegogo Crowdfunding Campaign for Pediatric Rare Diseases SOM Biotech -located at the Barcelona Science Park- has launched a crowdfunding campaign, through the American-based platform Indiegogo, to raise at least 300,000 $USD in donation funds for five new R&D projects in pediatric rare diseases. These are Cystic Fibrosis, Duchenne Muscular Dystrophy, Gaucher Disease, Niemann Pick Disease Type C, and Osteogenesis Imperfecta.
  View more
3 December 2015
Spanish university students show a high degree of ignorance about the human papillomavirus (HPV) and its consequences Sanofi Genzyme
Spanish university students show a high degree of ignorance about the human papillomavirus (HPV) and its consequences Spanish university students show a high degree of ignorance about the human papillomavirus (HPV) and its consequences
  View more
3 December 2015
Spanish university students show a high degree of ignorance about the human papillomavirus (HPV) and its consequences Sanofi Genzyme
Spanish university students show a high degree of ignorance about the human papillomavirus (HPV) and its consequences Spanish university students show a high degree of ignorance about the human papillomavirus (HPV) and its consequences
  View more
24 November 2015
Media, social networks and health professionals influence the parents' decision on vaccination Sanofi Genzyme
Media, social networks and health professionals influence the parents' decision on vaccination.
  View more
18 November 2015
More than two thirds of 'anti vaccine' websites using false scientific evidence and personal anecdotes Sanofi Genzyme
Según revela un estudio liderado por la Escuela de Salud Pública Johns Hopkins Bloomberg de Baltimore, presentado recientemente en el encuentro anual de la Asociación Americana de Salud Pública de Chicago y que ha analizado 500 sitios online de colectivos antivacunas.
  View more
17 November 2015
New Biosearch Life's study: probiotics for the breast pain during lactation Biosearch S.A.
New Biosearch Life's study: probiotics for the breast pain during lactation Biosearch Life has presented the results from the study with its strain Lactobacillus fermentum CECT5716 for the reduction of the breast pain in women during lactation.
  View more
13 November 2015
SOM Biotech and Vall d'Hebron successfully complete a clinical trial in patients with TTR amyloidosis Parc Científic de Barcelona (PCB)
SOM Biotech and Vall d'Hebron successfully complete a clinical trial in patients with TTR amyloidosis SOM Biotech and the Vall d'Hebron Research Institute (VHIR) have successfully completed a Phase IIa proof-of-concept clinical trial in humans to evaluate the efficacy and safety of an innovative oral therapy for transthyretin amyloidosis (TTA), a rare disease that affects the peripheral nervous system and heart.
  View more
11 November 2015
The European Medicines Agency Safety Committee concludes that evidence does not support that HPV vaccines cause CRPS or POTS Sanofi Genzyme
The European Medicines Agency Safety Committee concludes that evidence does not support that HPV vaccines cause CRPS or POTS
  View more
30 October 2015
Mind the byte concludes the biggest round of biotech crowd-equity in Spain Parc Científic de Barcelona (PCB)
Mind the byte concludes the biggest round of biotech crowd-equity in Spain In just 43 days, bioinformatics company Mind the Byte, which specializes in services for computational drug design and is located in the Barcelona Scientific Park (PCB), has concluded an investment round totalling €234,310, through the Crowdcube crowdequity platform .
  View more
22 October 2015
Increasingly close to eradicating polio through vaccination Sanofi Genzyme
Increasingly close to eradicating polio through vaccination
  View more
20 October 2015
The Spanish Vaccinology Association pays tribute to one of the Spaniards who lost his life trying to eradicate smallpox Sanofi Genzyme
The Spanish Vaccinology Association pays tribute to one of the Spaniards who lost his life trying to eradicate smallpox The Spanish Vaccinology Association pays tribute to one of the Spaniards who lost his life trying to eradicate smallpox
  View more
18 October 2015
PCB will host the VII Spanish Drug Discovery Network Meeting Parc Científic de Barcelona (PCB)
PCB will host the VII Spanish Drug Discovery Network Meeting From 12 to 13 November the Barcelona Science Park (PCB) will host the VII Spanish Drug Discovery Network Meeting, which will bring together, once more year, renowned members from the international academia, scientific and business communities to debate and exchange knowledge about the latest advances in chemical biology, drug discovery and translational research.
  View more
16 October 2015
Artax is granted 10 million dollars to foster clinical trials with an innovative drug in patients who suffer from autoimmune disorders Parc Científic de Barcelona (PCB)
Artax is granted 10 million dollars to foster clinical trials with an innovative drug in patients who suffer from autoimmune disorders The start-up Artax Biopharma –focusing on the development of first-in-class drugs to treat autoimmune diseases- has closed a Series B series investment funding round totaling $10 Million to boost clinical trials of its most advanced compound, drug AX- 024.
  View more
14 October 2015
Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M) Ysios Capital Partners SGEIC, S.A
Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M) Funds will help company reach clinical validation for lead candidate in X-ALD, a rare neurodegenerative and life-threatening disease
  View more
8 October 2015
'Health & Bio Team Dating', a new initiative to bring together entrepreneurs and scientists Parc Científic de Barcelona (PCB)
On 3 December 2015, Banc Sabadell jointly three entities located at the Barcelona Science Park (PCB) –Biocat, CataloniaBio and the Bosch i Gimpera Foundation (FBG)– are holding Health & Bio Team Dating, a meeting that will help develop an bioentrepreneur ecosystem to catalyze the creation of new business projects.
  View more
8 October 2015
'Health & Bio Team Dating', a new initiative to bring together entrepreneurs and scientists Parc Científic de Barcelona (PCB)
'Health & Bio Team Dating', a new initiative to bring together entrepreneurs and scientists On 3 December 2015, Banc Sabadell jointly three entities located at the Barcelona Science Park (PCB) –Biocat, CataloniaBio and the Bosch i Gimpera Foundation (FBG)– are holding Health & Bio Team Dating, a meeting that will help develop an bioentrepreneur ecosystem to catalyze the creation of new business projects.
  View more
7 October 2015
Bionaturis unveils the development of six new biotech products BIONATURIS GROUP
Bionaturis unveils the development of six new biotech products -Five of these new drugs point to Animal Health sector that represents a $100 billion global annual worldwide market
-Broadening its portfolio Bionaturis Group strengthens its position as a reference partner to develop biological products for animal health from livestock to pets
  View more
30 September 2015
The Basque biotechnology company OWL will support the israeli Galmed in developing drugs against liver disease One Way Liver, SL. (OWL)
The alliance allows the use of the non-invasive diagnostic test OWLiver in clinical trials of a drug against Non-Alcoholic Steatohepatitis (NASH) developed by Galmed.
Both companies agreed also the searching for new markers to predict a patient's response to treatment.
  View more
29 September 2015
Control of Human Papillomavirus (HPV) requires a coordinated and comprehensive strategy for both sexes Sanofi Genzyme
Control of Human Papillomavirus (HPV) requires a coordinated and comprehensive strategy for both sexes
  View more
22 September 2015
Back to school increases the risk of infection by rotavirus Sanofi Genzyme
Back to school increases the risk of infection by rotavirus
  View more
18 September 2015
Registration starts for the 2015-2016 'Recerca en Societat' program at the Barcelona Science Parc Parc Científic de Barcelona (PCB)
Registration starts for the 2015-2016 'Recerca en Societat' program at the Barcelona Science Parc This upcoming 8 October, the Barcelona Science Park (PCB) opens the enrollment period to participate in the experimental workshops 'Fes recerca!' (Do Research!) and 'Descobreix la recerca!' (Discover Research!), which gives the start to the 15th edition of 'Recerca in Societat' (Research in Society), involving annually about 5,000 people.
  View more
18 September 2015
Biosearch Life is revamping its corporate visual identity and unveils its new website Biosearch S.A.
Biosearch Life is revamping its corporate visual identity and unveils its new website Biosearch Life, a biotechnology company engaged in the development, manufacturing and marketing of functional ingredients for the pharmaceutical and food industry, unveils its new corporate visual identity. This is aimed at renewing its image reflecting its values which shall be implemented in the different products it offers.
  View more
17 September 2015
Sanofi Pasteur MSD and a group of experts publish a special issue on the economic value of vaccination Sanofi Genzyme

Sanofi Pasteur MSD and a group of experts publish a special issue
on the economic value of vaccination
  View more
15 September 2015
Mind the Byte opens a branch in Denmark and launches a crowdfunding campaign Parc Científic de Barcelona (PCB)
Mind the Byte opens a branch in Denmark and launches a crowdfunding campaign Mind the Byte –located at Barcelona Science Park (PCB) and specializing in the development of cloud technologies for drug discovery– just opened a branch at the Copenhagen Bio Science Park (COBIS), as a first step in the internationalization that the star-up has started with the strategic support of the Government of Catalonia.
  View more
8 September 2015
Sanifit raises €36.6M ($41.3M) in Series C financing round Ysios Capital Partners SGEIC, S.A
Sanifit raises €36.6M ($41.3M) in Series C financing round Financing will advance Sanifit’s lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification and through phase II/III for calciphylaxis
  View more
25 August 2015
The incidence of genital warts decreased by 72% in women aged 16 to 22 years following the HPV vaccine introduction Sanofi Genzyme
The incidence of genital warts decreased by 72% in women aged 16 to 22 years following the HPV vaccine introduction
  View more
19 August 2015
Recent studies point to family history as a new risk factor for developing shingles Sanofi Genzyme
Recent studies point to family history as a new risk factor for developing shingles
  View more
7 August 2015
Jordi Quintana, member of the Executive Board of IRDiRC´s 'Data Mining and Repurposing Task Force' Parc Científic de Barcelona (PCB)
Jordi Quintana, member of the Executive Board of IRDiRC´s 'Data Mining and Repurposing Task Force' Jordi Quintana, head of the Drug Discovery Plaform at the Barcelona Science Park (PCB), has been appointed member of the Executive Board of the Data Mining and Repurposing Task Force of the International Rare Diseases Research Consortium (IRDiRC).
  View more
5 August 2015
Sylvie Bove, new CEO of EIT Health Parc Científic de Barcelona (PCB)
Sylvie Bove, new CEO of EIT Health Sylvie Bove has been appointed as new CEO of the EIT Health, the Knowledge and Innovation Community (KIC) for healthy living and active aging, promoted by the European Institute of Innovation and Technology (EIT). The Spanish node, EIT Health Spain, headed by the University of Barcelona (UB) with the support from Biocat, has its headquarters at Barcelona Science Park (PCB).
  View more
4 August 2015
Mind the Byte granted funding from the SME Instrument from the European Union Parc Científic de Barcelona (PCB)
Mind the Byte granted funding from the SME Instrument from the European Union Mind the Byte –a company specializing in the provision of services and solutions in computational drug design based at Parc Cientific de Barcelona (PCB)– has been selected in the last call of the SME Instrument of the European Commission and will receive 50,000 Euros to carry out the feasibility study of the Datanimbus project.
  View more
4 August 2015
A study confirms the risk of HPV infected men develop external genital lesions Sanofi Genzyme
El diseño de programas de vacunación frente al VPH destinado únicamente a mujeres y a niñas, refuerza la creencia de que el VPH sólo afecta a las mujeres. Sin embargo, el VPH también afecta a los varones, quienes pueden llegar a desarrollar patologías como cáncer anal, de pene o verrugas genitales.
  View more
14 July 2015
SM Genomics will make available to the amateur athlete a genetic test which assesses susceptibility to injury Parc Científic de Barcelona (PCB)
SM Genomics will make available to the amateur athlete a genetic test which assesses susceptibility to injury SM Genomics, a spin-off of the University of Barcelona (UB) based at the Barcelona Science Park (PCB), has just opened a financing round of 450,000 € to bring to the amateur sport Spanish market their Genetic Injury Report (GIR).
  View more
9 July 2015
It advocates a global agreement for the right of the child to proper immunization Sanofi Genzyme
It advocates a global agreement for the right of the child to proper immunization
  View more
8 July 2015
Experts in favor of opening debate on the current financing model of vaccines Sanofi Genzyme
Experts in favor of opening debate on the current financing model of vaccines
  View more
3 July 2015
SUMA agreement that will boost the PCB-PRBB Animal Facility Alliance is signed Parc Científic de Barcelona (PCB)
SUMA agreement that will boost the PCB-PRBB Animal Facility Alliance is signed On Monday June 29 an agreement was signed between the Barcelona Science Park (PCB), the Barcelona Biomedical Research Park (PRBB) and the CERCA Institute that will foster the development of the PCB-PRBB Animal Facility Alliance.
  View more
1 July 2015
Sanofi Pasteur and Merck Vaccines appoint David Khougazian as President of Sanofi Pasteur MSD Sanofi Genzyme
Sanofi Pasteur and Merck Vaccines appoint David Khougazian as President of Sanofi Pasteur MSD Sanofi Pasteur and Merck Vaccines appoint David Khougazian
as President of Sanofi Pasteur MSD
  View more
29 June 2015
Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia Sanofi Genzyme
Human papillomavirus vaccination is changing the epidemiologyof high-grade cervical lesions in Australia
  View more
22 June 2015
The second national program of systematic vaccination against shingles in people over 65 and 74 starts in France Sanofi Genzyme
The second national program of systematic vaccination against shingles in people over 65 and 74 starts in France
  View more
19 June 2015
Era7 Bioinformatics is exhibiting at the Festival of Genomics in Boston, booth #54 Era7 Information Technologies
Era7 Bioinformatics is exhibiting at the Festival of Genomics in Boston, booth #54 Era7 Bioinformatics will be exhibiting in the first Festival of Genomics held in Boston (MA) from 22nd to 24th June 2015 and organized by FrontLine Genomics.
  View more
18 June 2015
DoPlanning will be presented at the Cambridge Innovation Center in Boston Era7 Information Technologies
DoPlanning, a very simple productivity tool that provides a web-hosted access to all the information generated by your organization, will be presented at the Cambridge Innovation Center in Boston on June 26, at 12:00 local time, 18:00 Spanish hour in the Charles room . The presentation will be given by Eduardo Pareja, CEO of Era7.
  View more
18 June 2015
Andalusian companies join forces in the development of healthy oils and fats Biosearch S.A.
Andalusian companies join forces in the development of healthy oils and fats Five companies of Andalusia, the world's largest producer of olive oil, have joined forces in the last two years, in the development of technologies that enable the production of oils and fats with nutritional and technological improvements, to be incorporated in food products maintaining their organoleptic qualities.
  View more
17 June 2015
Biosearch Life gets GMP certificate for its extracts manufacturing plant Biosearch S.A.
The Spanish Agency for Medicines and Health Products (AEMPS) has approved the GMP Certificate (Good Manufacturing Practices) for Biosearch Life as a manufacturer of active substances of use in herbal medicinal products.
  View more
17 June 2015
GARDASIL®9: New HPV vaccine approved in the European Union Sanofi Genzyme
GARDASIL®9: New HPV vaccine approved in the European Union
  View more
16 June 2015
Kendall Square, in which Era7 has an office since 2012, is considered Boston’s biotech hub Era7 Information Technologies
Kendall Square, in which Era7 has an office since 2012, is considered Boston’s biotech hub Kendall Square is the core of Boston’s rich biotechnology industry as both large and small firms are trying to get a spot and take part of its increible success.
  View more
10 June 2015
The vaccine against HPV proves to be effective and safe in women and men Sanofi Genzyme
The vaccine against HPV proves to be effective and safe both in women and men
  View more
25 May 2015
Vaccination against HPV, is effective in men? Sanofi Genzyme
Vaccination against HPV, is effective in men?
  View more
25 May 2015
Next week Era7 Bioinformatics will exhibit at ASM 2015 in New Orleans: booth 777 Era7 Information Technologies
Next week Era7 Bioinformatics will exhibit at ASM 2015 in New Orleans: booth 777 Four people from Era7 will attend the American Society for Microbiology (ASM) 2015 congress in New Orleans , Louisiana. After the great experience in Boston in 2014, this year we will exhibit again and this year we will also present two posters about Genomics and Metagenomics.
  View more
20 May 2015
New Publication: Metagenomic Analysis of Milk of Healthy and Mastitis-Suffering Women Era7 Information Technologies
Era7 Bioinformatics team participates in another scientific publication: Metagenomic Analysis of Milk of Healthy and Mastitis-Suffering Women (http://www.ncbi.nlm.nih.gov/pubmed/25948578).
  View more
15 May 2015
Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company Ysios Capital Partners SGEIC, S.A
Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company Option may be exercised based on Phase II trial results for recombinant human Alkaline Phosphatase
  View more
14 May 2015
The digital training of health professionals is key in the development of health sector Sanofi Genzyme
The digital training of health professionals is key in the development of health sector
  View more
12 May 2015
The pain caused by shingles, which affected in 2014 to more than 30,000 Catalan, is one of the most disabling Sanofi Genzyme
The pain caused by shingles, which affected in 2014 to more than 30,000 Catalans, is one of the most disabling
  View more
12 May 2015
Regional experts emphasise the need to work actively in the publication of an adult immunization schedule in the Basque Country Sanofi Genzyme
Regional experts emphasise the need to work actively in the publication of an adult immunization schedule in the Basque Country
  View more
7 May 2015
TransLink project will host the “2015 Glycoimmunology Training Course” at Tel Aviv University, Israel INKEMIA IUCT GROUP
The TransLink project is pleased to host the 2015 Glycoimmunology Training Course to share knowledge in the area of degeneration of BHV and bring closer excellent scientist to immunological responses involved in this process.Six travel grants will be allocated.
  View more
30 April 2015
European project to develop an innovative therapeutic strategy against epilepsy Parc Científic de Barcelona (PCB)
European project to develop an innovative therapeutic strategy against epilepsy The European project «ECMED» has been launched recently. It is aimed to design, validate and bring into practice new innovative therapeutic strategies to further the development of a treatment and a diagnostic approach for the management of epilepsy. Iproteos is the only Spanish partner of the consortium.
  View more
29 April 2015
Centro de Estudios Superiores de la Industria Farmacéutica

• Para esta VIII Edición del Máster en Biotecnología de la Salud CESIF apuesta, una vez más, por una formación práctica que permita a los alumnos la aplicación inmediata de los conocimientos adquiridos en entornos laborales actuales.

• Un Programa dirigido a formar profesionales en el Sector, ofreciendo una visión completa del origen, situación actual y futuro, de la empresa biotech.
  View more
28 April 2015
As childhood vaccines don´t protect for a lifetime, the importance of adult vaccination has been stressed. Sanofi Genzyme
As childhood vaccines don´t protect for a lifetime, the importance of adult vaccination has been stressed.
  View more
24 April 2015
Sanofi Pasteur MSD voted one of the best 50 great place to work in Spain Sanofi Genzyme
Sanofi Pasteur MSD voted one of the best 50 great place to work in Spain
  View more
22 April 2015
The IBMB-CSIC Structural Biology Unit has been awarded a "María de Maeztu" distinction Parc Científic de Barcelona (PCB)
The IBMB-CSIC Structural Biology Unit has been awarded a The Structural Biology Unit of the Institute of Molecular Biology of Barcelona (IBMB-CSIC), located at Parc Científic de Barcelona, has obtained the accreditation of Unit of Excellence “María de Maeztu” in the first edition of this call of the Ministry of Economy and Competitiveness. By virtue of this recognition, the research unit will be endowed with 500,000 € per year over the next four years.
  View more
22 April 2015
Experts argue for a unique and maximum vaccine calendar that contemplates all ages Sanofi Genzyme
Experts argue for a unique and maximum vaccine calendar that contemplates all ages
  View more
21 April 2015
Ordesa leads the Smartfoods project Parc Científic de Barcelona (PCB)
Ordesa leads the Smartfoods project The Centre for the Development of Industrial Technology (CDTI) has granted the Smartfoods industrial research project for the development of smart food to a consortium of companies led by Ordesa. This research will be conducted at the Ordesa R&D&i center at Parc Científic de Barcelona.
  View more
7 April 2015
COLARIS®: Hereditary Cancer Testing for Colorectal Cancer, Uterine Cancer Myriad Genetics España, S.L.U
COLARIS®: Hereditary Cancer Testing for Colorectal Cancer, Uterine Cancer COLARIS is a genetic test that assesses a persons risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine cancer. COLARIS detects disease-causing mutations in the MLH1, MSH2, MSH6, PMS2, EPCAM and MYH genes that are responsible for the majority of Lynch syndrome and MYH-associated polyposis (MAP) cases
  View more
31 March 2015
Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome Parc Científic de Barcelona (PCB)
Avizorex Pharma announces Grant of U.S. Patent for its treatment of dry eye syndrome Avizorex Pharma, a company developing novel therapeutics for Dry Eye Disease with offices in the Parc Científic de Barcelona, has announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for compositions and methods of treatment covering AVX-012, a topical treatment for Dry Eye with a new mechanism of action currently undergoing late-stage preclinical studies.
  View more
30 March 2015
GARDASIL® 9, new HPV vaccine from Sanofi Pasteur MSD granted positive opinion by European Committee for Medicinal Products for Human Use Sanofi Genzyme
GARDASIL® 9, new HPV vaccine from Sanofi Pasteur MSD granted positive opinion by European
Committee for Medicinal Products for Human Use
  View more
26 March 2015
Myriad Announces Prolaris® Test Biopsy Results From EMPATHY-P Myriad Genetics España, S.L.U
Myriad Announces Prolaris® Test Biopsy Results From EMPATHY-P Myriad Announces Prolaris® Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting
  View more
25 March 2015
Experts advocate prevention in order to avoid dependency and encourage healthy aging Sanofi Genzyme
Experts advocate prevention in order to avoid dependency and encourage healthy aging
  View more
18 March 2015
PROTEOS INVOLVED IN THE FP7 MARIE CURIE PROGRAM “MICROSMETICS” PROTEOS BIOTECH, S.L.
PROTEOS INVOLVED IN THE FP7 MARIE CURIE PROGRAM “MICROSMETICS” INDUSTRY AND ACADEMIA JOIN FORCES FOR THE EXPLOITATION OF MICROBIAL BIODIVERSITY FOR PRODUCING NOVEL COSMECEUTICALS.
  View more
17 March 2015
Taller de Introducción a Normas de correcta fabricación (NCF/GMPs) Lean GxP Support S.L
Taller de Introducción a Normas de correcta fabricación (NCF/GMPs) ¿Quieres conocer un sistema GMP?
¿Necesitas certificarte para dar valor a tus servicios?
¿Quieres saber por dónde empezar?
  View more
9 March 2015
Enantia's cocrystallization technology endorsed by global partnership Parc Científic de Barcelona (PCB)
Enantia's cocrystallization technology endorsed by global partnership An innovative cocrystal, obtained by Enantia –based at the Parc Científic de Barcelona– working in collaboration with Esteve R&D, is part of the global partnership recently announced by Esteve and Mundipharma-Purdue.
  View more
9 March 2015
The concern for preventing serious, painful or chronic diseases increases over age 50 Sanofi Genzyme
The concern for preventing serious, painful or chronic diseases increases over age 50
  View more
6 March 2015
Aura Biosciences Closes $21M Series B Financing Ysios Capital Partners SGEIC, S.A
Aura Biosciences Closes $21M Series B Financing Aura Biosciences, a biotech company developing highly tumor-targeted breakthrough therapies for rare cancers, has secured a $21M Series B round of
funding. The financing was led by Advent Life Sciences, with participation from new investors, Chiesi Ventures, Ysios Capital, and Alexandria Venture Investments. Existing investors, including LI-COR Biosciences and Henri Termeer, former Chief Executive Officer of Genzyme, also participated in the
financing.
  View more
5 March 2015
Vaccination against HPV shows high effectiveness in reducing high-grade cervical lesions Sanofi Genzyme
Vaccination against HPV shows high effectiveness in reducing high-grade cervical lesions
  View more
4 March 2015
Discover our binding kinetics platform at FarmaForum 2015 Enzymlogic
Discover our binding kinetics platform at FarmaForum 2015 A binding kinetics platform that guides the kinetic optimization of drug candidates and accelerates the drug discovery process.
  View more
27 February 2015
iMols, the Mind the Byte cloud platform for drug discovery, is now available free of charge Parc Científic de Barcelona (PCB)
iMols, the Mind the Byte cloud platform for drug discovery, is now available free of charge
Mind the Byte –based at the Parc Científic de Barcelona and specializing in the provision of services and solutions for computational drug discovery- has opened cloud platform for use by the scientific, academic and business community. iMols is the first cloud platform specifically designed for drug discovery using the SaaS (‘Software as a Service') approach.
  View more
24 February 2015
Intelligent Pharma sets up office in Canada and expands into the petrochemical market Parc Científic de Barcelona (PCB)
Intelligent Pharma sets up office in Canada and expands into the petrochemical market Intelligent Pharma – based at the Parc Científic de Barcelona, and specializing in computational chemistry services for the pharmaceutical and biotech industry- just opened an office in Calgary (Alberta), Canada. This is the fourth international office that the company sets up, after the opening of two European delegations, in Germany and United Kingdom and another one in the United States.
  View more
24 February 2015
Prexton Therapeutics raises €8.7 million ($10 million) in a Series A round Ysios Capital Partners SGEIC, S.A
Prexton Therapeutics raises €8.7 million ($10 million) in a Series A round Swiss-Based start-up attracts venture funding from leading European VC firms to address Parkinson’s disease and other CNS conditions
  View more
12 February 2015
mAbxience acquires 100% of biopharmaceutical Genhelix MABXIENCE
mAbxience acquires 100% of biopharmaceutical Genhelix Spanish-based Chemo Group, has purchased 100% of the Genhelix biopharmaceutical plant, located in Spain. The operation is one of the biggest investments ever made by a Spanish company in a biotechnology project. mAbxience, a pioneer in biosimilar monoclonal antibodies, has an ambitious investment plan in the new plant to increase its capacity up to 16,000 litres in the coming years.
  View more
11 February 2015
With a risk of infection of 75%, HPV is one of the most prevalent STDs, and made also cause cancer Sanofi Genzyme
With a risk of infection of 75%, HPV is one of the most prevalent STDs, and made also cause cancer
  View more
9 February 2015
Hexyon® (Sanofi Pasteur MSD) receives positive opinion from CHMP for a new administration guideline in the EU Sanofi Genzyme
Hexyon® (Sanofi Pasteur MSD) receives positive opinion from CHMP for a new administration guideline in the EU
  View more
9 February 2015
New publication by Era7’s team in Genome Announcements Era7 Information Technologies
New publication by Era7’s team in Genome Announcements Marina Manrique and Raquel Tobes, part of Era7’s team, participated in the scientific paper “Complete Genome Sequence of Ehrlichia mineirensis, a Novel Organism Closely Related to Ehrlichia canis with a New Host Association” that has been recently published in Genome Announcements.
  View more
28 January 2015
«Spark», a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia Parc Científic de Barcelona (PCB)
«Spark», a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia The project, which has just won a 500,000 euro endorsement from the Ministry of Economy and Finance, will be developed by a consortium led by Iproteos, located at the Parc Cientific de Barcelona. The drug candidate is IPR019, that belongs to a family of compounds of so-called 'third generation', has been developed and patented by this biotech.
  View more
22 January 2015
Biosearch Life applies for a patent on Probiotic bacterias regulating cholesterol levels Biosearch S.A.
Biosearch Life has recently registered an application for a new patent to protect two new probiotic strains for use in the control of Hypercholesterolemia: Probiotic strains having cholesterol absorbing capacity, methods and uses thereof”.
  View more
15 December 2014
PRESENT AND FUTURE OF VACCIONOLOGY- 11 ESSENTIAL REFLECTIONS Sanofi Genzyme
On the occasion of the celebration of the 20th anniversary of Sanofi Pasteur MSD has published the book "Present and future of vaccionology. 11 essential reflections" which is discussed along its ten chapters about present and future vaccines and their journey along the history and major achievements thanks to its discovery
  View more
14 December 2014
¿Cómo se pueden financiar las ‘start up’ biotecnológicas? Enzymlogic
¿Cómo se pueden financiar las ‘start up’ biotecnológicas? Pública y privada; campañas de 'crowdfunding' y programas de aceleradoras. Las vías por las que se nutren de capital las 'biotec' son las mismas que las de cualquiera, pero las condiciones suelen ser más exigentes.
  View more
11 December 2014
Parents and pediatricians 2.0 connected for proper child protection Sanofi Genzyme
Barcelona hosts the I meeting 2.0 "A great defense for bugs " in order to solve the most common concerns of mothers 2.0 on their children’s care: how to protect their babies from the womb and during the first months of their lives.
  View more
3 December 2014
SANOFI PASTEUR MSD CELEBRATES ITS 20TH ANNIVERSARY REAFFIRMING ITS COMMITMENT TO HEALTH Sanofi Genzyme
SANOFI PASTEUR MSD CELEBRATES ITS 20TH ANNIVERSARY REAFFIRMING ITS COMMITMENT TO HEALTH Sanofi Pasteur MSD, the European leading company in prevention and vaccines , celebrates its 20th anniversary with a review of these two decades of service to society and commitment to public health.
  View more
25 November 2014
Cytology and vaccination are designated as effective methods of control and prevention of HPV in Catalonia Sanofi Genzyme
Cytology and vaccination are designated as effective methods of control and prevention of HPV in Catalonia
  View more
24 November 2014
SOM Biotech and the Vall d’Hebron Hospital have initiated a clinical trial in patients using a new repositioned drug for amyloidosis Parc Científic de Barcelona (PCB)
SOM Biotech and the Vall d’Hebron Hospital have initiated a clinical trial in patients using a new repositioned drug for amyloidosis
SOM Biotech -located at the Parc Científic de Barcelona- and the Vall d'Hebron University Hospital have started to administer to patients compound SOM0226, a repositioned drug for the treatment of transthyretin amyloidosis.The hospital will assume, jointly with SOM Biotech, the risks and the return on investment of the clinical development of the drug.
  View more
19 November 2014
Enzymlogic to take part in the VI SDDN Meeting Enzymlogic
Enzymlogic to take part in the VI SDDN Meeting Enzymlogic to be present at the next Spanish Drug Discovery Network Meeting to share ideas and explore new tools that will add real value to its customers' drug discovery projects.
  View more
19 November 2014
XI Conference Andalusian Health Researches FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD
XI Conference Andalusian Health Researches On December 4 will be celebrate at the Reina Sofia Hospital, Cordoba, the XI Conference Andalusian Health Researches, promoted by Consejería de Igualdad, Salud y Políticas Sociales and organized by Fundación Progreso y Salud.
  View more
14 November 2014
Master Degree in Management and Research Results Transfer in Health Sciences FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD
Master Degree in Management and Research Results Transfer in Health Sciences Health promotes the first Master Degree in Management and Research Results Transfer in Health Sciences.
In collaboration with the universities of Seville and Málaga, within the framework of the Campus of International Excellence Andalusia Tech, consists of different modules that include R&D management, legal issues, marketing, venture capital or business development, among others.
  View more
13 November 2014
Era7 Bioinformatics is now a member of The Global Alliance for Genomics and Health Era7 Information Technologies
Era7 Bioinformatics is now a member of The Global Alliance for Genomics and Health Era7 Bioinformatics is proud to announce that it has recently become member of The Global Alliance for Genomics and Health. The Global Alliance is an international coalition formed to facilitate the sharing of genomical and clinical data, with the intention of promoting potential advancements in medicine and science.
  View more
6 November 2014
Medicinas más eficientes con menos tomas. Enzymlogic
Medicinas más eficientes con menos tomas. Las técnicas de Enzymlogic permiten a los laboratorios producir fármacos más innovadores y ayudan a reducir el número de dosis diarias.
  View more
31 October 2014
Era7 Bioinformatics’ Bio4j project team attends final meeting of Google Summer of Code 2014 in California Era7 Information Technologies
Era7 Bioinformatics’ Bio4j project team attends final meeting of Google Summer of Code 2014 in California Bio4J was selected this year as a project for being funded by the Google Summer of Code 2014. After months of work, the program ended with a really successful participation of Era7 Bioinformatics team.
  View more
27 October 2014
New section 'NGS Media' on Era7 Bioinformatics website Era7 Information Technologies
New section 'NGS Media' on Era7 Bioinformatics website We are launching today in Era7 Bioinformatics website a new section called NGS media, in which you will find animations explaining some important concepts and methods related to Next Generation Sequencing.
  View more
22 October 2014
Enzymlogic participates in public-private collaboration to investigate inborn errors of metabolism diseases Enzymlogic
Enzymlogic participates in public-private collaboration to investigate inborn errors of metabolism diseases Enzymlogic provides binding kinetics expertise to a RETOS-COLABORACION project supported with €1.1 million funding from the Spanish Ministry of Economy and Competitiveness.
  View more
16 October 2014
InKemia IUCT enters the capital of Mind the Byte Parc Científic de Barcelona (PCB)
InKemia IUCT enters the capital of Mind the Byte Mind the Byte -located at the Parc Científic de Barcelona (PCB)- and specialized in cloud computing C solutions for biomedical and biotechnological research has just closed a funding round of 200,000 € to accelerate the development and commercialization of its SaaS platforms (Software as a Service) for drug discovery. This capital increase has been led by InKemia IUCT Group, which has acquired a 5% stake in shares.
  View more
14 October 2014
Presentation of Era7's new service for Cancer Genomics, Genome7, in BioSpain 2014 Era7 Information Technologies
Presentation of Era7's new service for Cancer Genomics, Genome7, in BioSpain 2014 On 24 September 2014 Eduardo Pareja, CEO of Era7, presented for the first time in BioSpain 2014 (Santiago de Compostela) in a press conference Era7’s new service for Cancer Genomics, Genome7.
  View more
24 September 2014
Join Enzymlogic at Biospain 2014 Enzymlogic
Join Enzymlogic at Biospain 2014 Enzymlogic is attending the 7th international meeting on biotechnology that will be held in Santiago the Compostela, Spain, on September 24th to 26th, 2014.
  View more
15 September 2014
ABC Sevilla echoes Era7 Bioinformatics' plans of international growth Era7 Information Technologies
ABC Sevilla echoes Era7 Bioinformatics' plans of international growth Last Saturday, 13th September 2014, ABC Sevilla spread in its newspaper the news about the plans to grow internationally the Bacterial Genomics company, Era7 Bioinformatics, has.
  View more
1 September 2014
Rafer SL invests in Spanish NGS leader Era7 Bioinformatics to accelerate Era7's International expansion plan Era7 Information Technologies
Rafer SL invests in Spanish NGS leader Era7 Bioinformatics to accelerate Era7's International expansion plan Era7 Bioinformatics and Comercial Rafer announced that Rafer has made an strategic investment in Era7 Bioinformatics to accelerate the International expansion of Era7 Bioinformatics, the bacterial genomics company. This expansion will target specially the US market.
  View more
18 August 2014
Era7 Bioinformatics, The Bacterial Genomics Company, will be attending BIOSPAIN 2014 – Santiago de Compostela, Spain 24 – 26 September 2014 Era7 Information Technologies
Era7 Bioinformatics, The Bacterial Genomics Company, will be attending BIOSPAIN 2014 – Santiago de Compostela, Spain 24 – 26 September 2014 We will be attending BIOSPAIN 2014, an International meeting on Biotechnology that is being held this year in Santiago de Compostela from 24th to 26th September. At the meeting, our team of Era7 Bioinformatics will be announcing new Next Generation Sequencing services and we will meet our customers, partners and collaborators both at the booth and at the Partnering event.
  View more
3 July 2014
Iproteos, the first biotech to launch an equity crowdfunding campaign in Spain Parc Científic de Barcelona (PCB)
Iproteos, the first biotech to launch an equity crowdfunding campaign in Spain The Catalan biotech Iproteos –based at the Parc Cientific de Barcelona– has launched an innovative funding campaign based on equity crowdfunding- through the Creoentuproyecto.com platform– which aims to raise 100,000 € to complete the non-regulatory preclinical stage of its compound IPR019. This compound is one of the 20 drugs across the world that is being developed to slow-down the progression of schizophrenia and revert the cognitive deficits of this disease.
  View more
17 June 2014
Abierto el plazo de matrícula para cursar el Máster de Biotecnología de la Salud de CESIF durante el Curso Académico 2014/2015 Centro de Estudios Superiores de la Industria Farmacéutica
Abierto el plazo de matrícula para cursar el Máster de Biotecnología de la Salud de CESIF durante el Curso Académico 2014/2015 Se encuentra abierto el plazo de matrícula para cursar la VII Edición del Programa Máster en Biotecnología de la Salud de CESIF, dirigido tanto a recién licenciados en Ciencias de la Salud, como a profesionales del sector sanitario y biotecnológico interesados en adquirir una sólida especialización en la gestión de las diferentes áreas de las empresas de Biotecnología Sanitaria, Agroalimentaria, Industrial y del Sector en general.
  View more
12 June 2014
Centro de Estudios Superiores de la Industria Farmacéutica
A través de este Programa CESIF pone a disposición de las empresas biotech la candidatura de los alumnos del Máster en Biotecnología de la Salud 2013/2014, que podrán incorporarse a los equipos de trabajo de las compañías que lo deseen a través del Convenio de Prácticas de CESIF.
  View more
10 June 2014
​Canvax is proudly General Sponsor for SEBBM´s Congress 2014. Canvax Biotech S.L.
​Canvax is proudly General Sponsor for SEBBM´s Congress 2014. Canvax, a biotech company located in Cordoba (Spain) is General Sponsor of the XXXVII Annual Congress of the Spanish Society of Biochemistry and Molecular Biology (SEBBM) event taking place in the city of Granada, from 9 to 12 September 2014.
  View more
2 June 2014
Meet us at the 15th Annual Drug Discovery Summit Enzymlogic
Meet us at the 15th Annual Drug Discovery Summit Enzymlogic attends at the 15th Annual Drug Discovery Leaders Summit, taking place this year on 2 & 3 June in Geneva, Switzerland.
  View more
28 May 2014
The second edition of SciCloud, the annual congress of reference in science and cloud services starts Parc Científic de Barcelona (PCB)
The second edition of SciCloud, the annual congress of reference in science and cloud services starts . The second edition of the "Annual Scientific Conference Cloud" (SciCloud 2014), the only congress specialized in science and cloud-computing services in Spain will be held on 19 June at the Auditorium at the Parc Cientific de Barcelona. The forum, organized by Mind the Byte, in collaboration with Microsoft, CataloniaBIO, and the PCB, will bring together renowned cloud computing experts from academia, business and government.
  View more
25 May 2014
Spanish Newspaper publishes an article about Era7 Bioinformatics and its growth in the United States Era7 Information Technologies
Spanish Newspaper publishes an article about Era7 Bioinformatics and its growth in the United States From Boston, Eduardo Pareja, CEO of Era7 Bioinformatics, answered several questions for the Spanish newspaper ABC.
  View more
23 May 2014
1st Day Networking on Research on Antibiotics Valoralia I+D
1st Day Networking on Research on Antibiotics Valoralia I más D, in collaboration with
The St George's University of London and the Antibiotic Discovery Network (AD-UK),
Organizes in Madrid on June 12 at 15:30 the 1st Day Networking Research on Antibiotics.
The main objectives of this event is to create a National Research Network Antibiotics (AD-SP)
For more information and registration send an e-mail to: youahid@valoraliaimasd.com
  View more
13 May 2014
Era7 Bioinformatics attending ASM 2014 at Boston. Visit us at booth #346 !! Era7 Information Technologies
Era7 Bioinformatics attending ASM 2014 at Boston. Visit us at booth #346 !! Era7 Bioinformatics will attend the American Society for Microbiology anual meeting from 16 to 20 of May 2014.
  View more
11 May 2014
Era7 Bioinformatics attending the ECCMID 2014 Conference at Barcelona Era7 Information Technologies
Era7 Bioinformatics attending the ECCMID 2014 Conference at Barcelona Era7 Bioinformatics is attending the ECCMID 2014 Conference at Barcelona and presenting three posters.
  View more
9 May 2014
Enzymlogic's CSO to present at the Protein Kinases in Drug Discovery Conference Enzymlogic
Enzymlogic's CSO to present at the Protein Kinases in Drug Discovery Conference Enzymlogic has been selected by the Advisory Board of the Protein Kinases In Drug Discovery Conference to give an Oral Presentation on May 9 in Berlin, Germany. The conference will host an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities, and will focus on drug discovery aspects within the protein kinases field.
  View more
8 May 2014
Enzymlogic sponsors the Protein Kinases in Drug Discovery Conference Enzymlogic
Enzymlogic sponsors the Protein Kinases in Drug Discovery Conference Enzymlogic is pleased to announce sponsorship of the upcoming Protein Kinases in Drug Discovery Conference held on May 8-9 in Berlin, Germany. The conference will host an exciting group of professionals from the academic, biotech, pharmaceutical, and business communities, and will focus on drug discovery aspects within the protein kinases field.
  View more
8 May 2014
Cinco alternativas de financiación y estrategia para hacer crecer con éxito tu proyecto Parc Científic de Barcelona (PCB)
Cinco alternativas de financiación y estrategia para hacer crecer con éxito tu proyecto
El próximo jueves 15 de mayo tendrá lugar, en el aula Fèlix Serratosa del Parc Científic de Barcelona (PCB,) la jornada de debate '¿Cómo financio mi proyecto?' que tiene como objetivo generar un espacio de encuentro para intercambiar opiniones y experiencias sobre las ventajas e inconvenientes de las actuales alternativas de financiación privada: Family, Friends & Fools (FFF), Business Angels, Capital Riesgo, Licensing y el Mercado Alternativo Bursátil (MAB).
  View more
22 April 2014
SOM Biotech develops a drug for Amyloidosis in collaboration with the Vall d’Hebron Research Institute SOM Biotech SL
SOM Biotech develops a drug for Amyloidosis in collaboration with the Vall d’Hebron Research Institute The VHIR and the biopharmaceutical SOM Biotech have signed an agreement to jointly develop the clinical phase of a drug for transthyretin Amyloidosis (ATTR). The collaboration starts with the execution of a proof of concept which will confirm the efficacy and safety of compound SOM0226. The product, a repositioned drug developed by SOM Biotech, has been designated recently orphan drug by the FDA.
  View more
24 March 2014
Parc Científic de Barcelona (PCB)

The University of Barcelona Biotech Development. –based at the PCB– have signed a agreement to develop a master's degree and postgraduate courses for the creation and management of biotech-based companies and knowledge transfer in the biopharmaceutical sector. The initiative will be developed in collaboration with ESEI International Business School, where the training programs will be given.
  View more
10 March 2014
Enzymlogic at Bio-Europe Spring 2014 Enzymlogic
Enzymlogic at Bio-Europe Spring 2014 Enzymlogic is attending the 8th Annual Bio-Europe Spring International Partnering Conference.
  View more
4 March 2014
The Health Challenge Enzymlogic
The Health Challenge Enzymlogic participates in the VII Annual Conference of the Biomedical Research Technological Platforms held in Barcelona on March 4th and 5th, 2014.
  View more
27 February 2014
Era7 Bioinformatics' Bio4j project has been selected for the Google Summer of Code 2014 Era7 Information Technologies
Era7 Bioinformatics' Bio4j project has been selected for the Google Summer of Code 2014 Google Summer of Code is a global program that offers students stipends to write code for open source projects. Google tries to identify and fund exciting projects like Bio4j.
  View more
27 February 2014
INTEGROMICS RELEASES NEW VERSION OF ITS QPCR DATA ANALYSIS SOFTWARE Integromics, S.L.
RealTime StatMiner® V5.0 Software Enhances Functionality and Improves Customer Experience
  View more
27 February 2014
Canvax, a new brand for Molecular Biology Reagents Canvax Biotech S.L.
Canvax, a new brand for Molecular Biology Reagents Canvax Biotech biotechnology has created a new brand to market their products laboratory focused on Molecular Biology Reagents.
  View more
19 February 2014
Biotech Development sets up its offices at the Parc Científic de Barcelona Parc Científic de Barcelona (PCB)
Biotech Development sets up its offices at the Parc Científic de Barcelona
Biotech Development, a consultancy company specializing in R&D+i, knowledge transfer and development of postgraduate training programs has just moved its headquarters to the Parc Científic de Barcelona. The startup wants to strengthen its business model and public-private collaborative partnerships to enhance its expansion strategy in the field of biotechnology.
  View more
1 February 2014
Enzymlogic ground-breaking services backed by ENISA funding Enzymlogic
Enzymlogic ground-breaking services backed by ENISA funding Enzymlogic, the first Spanish Contract Research Organization specialized in molecular mechanism of drug action analysis, has announced today that it has received major funding from the National Innovation Company (ENISA). ENISA is a public company attached to the Spanish Ministry of Industry, Energy and Tourism that, since 1982, has played an active role in the funding of viable and innovative business projects.
  View more
29 January 2014
HEALS, a European project for identifying an individual’s exposome and his impact on health Parc Científic de Barcelona (PCB)
HEALS, a European project for identifying an individual’s exposome and his impact on health
The Experimental Toxicology and Ecotoxicology Unit (UTOX) and Proteomics Platform of the Parc Científic de Barcelona participate in the European project «HEALS» which aims is to develop an integrated methodology to identify and decode an individual’s exposome.
  View more
18 January 2014
Dr. Eduardo Pareja, the CEO of Era7 Bioinformatics was invited to give a talk about metagenomics at The Royal College of Pathologists in London Era7 Information Technologies
Dr. Eduardo Pareja, the CEO of Era7 Bioinformatics was invited to give a talk about metagenomics at The Royal College of Pathologists in London The title of the talk was: "A New Cloud Computing System for Massive Analysis of Reads from Metagenomics Samples" was part of the Symposium "A New Era in Diagnostic Microbiology Pathogen Genomics; Tools and Challenges in the Control of Infectious Diseases", organized by the Health Protection Agency.
  View more
10 January 2014
SOM Biotech announces Orphan Drug Designation in US for SOM0226, a compound for the treatment of Transthyretin Amyloidosis (ATTR). SOM Biotech SL
The US FDA assigned Orphan Drug Designation to SOM Biotech SL for SOM0226 for the treatment of Transthyretin Amyloidosis (ATTR). This compound is indicated for all variants of the disease: Familial Amyloid Polyneuropathy (FAP), Familial Amyloid Cardiomyopathy (FAC), Senile Systemic Amyloidosis (SSA) and CNS Selective Amyloidosis (CNSA).
You will find the link to Press Release below.
  View more
2 January 2014
NIMGenetics primera empresa española certificada por Life Technologies Corporation para secuenciar exomas NIMGENETICS, GENÓMICA Y MEDICINA, SL
NIMGenetics primera empresa española certificada por Life Technologies Corporation para secuenciar exomas El laboratorio incorpora la tecnología Ion Proton™ a sus servicios para la secuenciación de exomas. La tecnología Ion Proton™ permite transformar la información genética en datos digitales a una velocidad y uniformidad no disponibles hasta el momento.
  View more
20 December 2013
Oryzon to attend the 32nd ANNUAL J.P. MORGAN Healthcare Conference in San Francisco Oryzon Genomics S.A.
Oryzon to attend the 32nd ANNUAL J.P. MORGAN Healthcare Conference in San Francisco Oryzon will attend the 32 J.P.MORGAN Conference next January, 2014 at the Westin St. Francis to discuss with the leaders of the industry the potential of epigenetics in devastating diseases. The company will also present at the parallel Biotech Showcase 2014 to be held at the Parc55 Wyndham the talk “LSD1 Inhibition stops cognitive impairment in CNS Diseases” on Jan 15th at 9:45 (Track B 4thFloor)
  View more
19 December 2013
VivaCell enhances its R&D drug discovery program with the European Community’s FP7 TRIFORC Project Vivacell Biotechnology España, S.L.
VivaCell enhances its R&D drug discovery program with the European Community’s FP7 TRIFORC Project VivaCell is member in the TriForC european Project for the research in new terpenoides, starting in 2013 and which is financed with 6,9 Million Euro in FP7.
  View more
17 December 2013
InKemia IUCT group gets a great European R + D of 6.0 Million € INKEMIA IUCT GROUP
InKemia IUCT group gets a great European R + D of 6.0 Million € IUCT, the division of knowledge InKemia group wins a competitive tender of the European Union leading a consortium of companies and research centers, with R & D project called "Developing a Biorefinery Glycerin to obtain products high quality and industrial value (GRAIL). "
  View more
16 December 2013
El Colegio Americano de Ginecología y Obstetricia (ACOG) y la Sociedad Americana de Medicina Materno-Fetal (SMFM) recomiendan el análisis cromosómico mediante microarrays para la evaluación genética de anomalías en el feto NIMGENETICS, GENÓMICA Y MEDICINA, SL
• NIMGenetics, empresa biotecnológica española, fue pionera en la utilización de la tecnología Array de CGH desarrollando el test KaryoNIM® Prenatal para la detección de alteraciones genéticas que comprometen severamente la salud y el desarrollo fetales.
  View more
3 December 2013
'Networking & Innovation Day ' a benchmark for fostering open innovation at the UB Group Parc Científic de Barcelona (PCB)
'Networking & Innovation Day ' a benchmark for fostering open innovation at the UB Group
More than 200 representatives from 160 organizations from the business and research community met at the Parc Científic de Barcelona, in the frame of the 'Networking & Innovation Day'.
  View more
27 November 2013
Canvax developed the most advanced technology in DNA Cloning Canvax Biotech S.L.
Canvax developed the most advanced technology in DNA Cloning Canvax Biotech, a 12 years old spanish biotech company has developed a new version of pSpark®, its DNA cloning system, obtaining the more efficient cloning vector market.
  View more
20 November 2013
UTOX - PCB receives the Certificate of Good Laboratory Practices which covers any kind of toxicological trial Parc Científic de Barcelona (PCB)
UTOX - PCB receives the Certificate of Good Laboratory Practices which covers any kind of toxicological trial
The Unit of Experimental Toxicology and Ecotoxicology (UTOX) at the Parc Cientific de Barcelona received the Certificate of assessment of conformity with Good Laboratory Practices (GLP), which covers the conduct of in vitro and in vivo studies on severe and chronic toxicity, mutagenicity tests, and ecotoxicological studies on human and veterinary drugs, health and cosmetic devices.
  View more
11 November 2013
The Berkeley Phylogenomics Group research team at the University of California, Berkeley, receives an NSF EAGER grant to develop a graph database and research environment for Big Data challenges in genomics, building on the Era7 Bioinformatics' Bio4j platform Era7 Information Technologies
The Berkeley Phylogenomics Group research team at the University of California, Berkeley, receives an NSF EAGER grant to develop a graph database and research environment for Big Data challenges in genomics, building on the Era7 Bioinformatics' Bio4j platform The Sjölander Lab at the University of California, Berkeley, has recently been awarded a 250K US dollars EAGER grant from the National Science Foundation to build a graph database for Big Data challenges in genomics. Naturally, they’re building on Bio4j.
  View more
7 November 2013
Madri+d interviews our CSO Patricia Alfonso Enzymlogic
"We feel passionate about the possibility to contribute to improving personalized medicine, which will doubtless be the medicine of the future."
  View more
30 October 2013
ALGENEX and BIOKIT sign a non-exclusive license agreement for IBES® technology to make faster high quality recombinant proteins for Diagnostics. ALGENEX (Alternative Gene Expression S.L.)
ALGENEX and BIOKIT are proud to announce the closing of a worldwide, non-exclusive license agreement for BIOKIT to use IBES® technology in its next generation in vitro diagnostics for human use. Under the license agreement, BIOKIT will produce a broad range of recombinant proteins.
  View more
29 October 2013
Perfil genético para una oncología personalizada: tratamiento adecuado a cada paciente: OncoNIM®Seq 50 para el diagnóstico oncológico personalizado NIMGENETICS, GENÓMICA Y MEDICINA, SL
Perfil genético para una oncología personalizada: tratamiento adecuado a cada paciente: OncoNIM®Seq 50 para el diagnóstico oncológico personalizado Secuenciación masiva para la identificación de mutaciones en 50 genes relacionados con el aparato digestivo, pulmón, mama, ovario, endometrio, sistema nervioso central y piel, así como tumores de origen desconocido
  View more
24 October 2013
Enzymlogic at the V Spanish Drug Discovery Network Conference Enzymlogic
Enzymlogic at the V Spanish Drug Discovery Network Conference Enzymlogic will present "Structure-kinetic relationship and kinetic selectivity profiling: toward the discovery and development of novel drugs".
  View more
22 October 2013
'Networking & Innovation Day': Solutions to technological and innovation challenges Parc Científic de Barcelona (PCB)
'Networking & Innovation Day': Solutions to technological and innovation challenges On the upcoming 28th of November, the University of Barcelona, the Bosch i Gimpera Bosch Foundation, the Scientific and Technological Centers of the UB and the Parc Científic de Barcelona will organize the first edition of 'Networking & Innovation Day' (NID). The objective of this initiative is to create a meeting point in the transfer of knowledge between research and business.
  View more
17 October 2013
Diagnóstico integral para el cáncer de mama y ovario hereditario NIMGENETICS, GENÓMICA Y MEDICINA, SL
Diagnóstico integral para el cáncer de mama y ovario hereditario OncoNIMSeq BRCA1/BRCA2 y OncoNIM Cáncer Familiar, dos herramientas para diagnóstico secuencial del cáncer de mama y ovario hereditario, basadas respectivamente en tecnologías de secuenciación masiva y de hibridación genómica comparada mediante microarrays (aCGH), una combinación que garantiza un diagnóstico integral, rápido y fiable
  View more
2 October 2013
AB-Biotics and Scienta Farma partner to sell a pharmacogenetic test in Mexico AB BIOTICS S.A.
The Spanish biotech company AB-Biotics, listed on the Spanish Alternative Stock Market (MAB), and Scienta Farma reached an agreement to sell the pharmacogenetic test Neurofarmagen in Mexico.
  View more
25 September 2013
A step forward in the treatment against pancreatic cancer Parc Científic de Barcelona (PCB)
A step forward in the treatment against pancreatic cancer A team of scientists from the BioMed Division at Leitat –based in the Parc Científic de Barcelona– and the University of Barcelona have shown the effectiveness of a new therapy for the treatment of cancer in preclinical trials. The new strategy is based on the action of a monoclonal antibody that is targeted against protein S100A4, a key factor in tumor development.
  View more
17 September 2013
Feynman Center. New Promega cGMP Manufacturing Facility Promega Biotech Ibérica S.L.
Feynman Center. New Promega cGMP Manufacturing Facility The Feynman Center is dedicated to serving customers in need of molecular biology reagents for in vitro diagnostic (IVD) assays.
  View more
9 September 2013
AB-Biotics granted European patent for cholesterol-lowering probiotic AB-Life AB BIOTICS S.A.
(Barcelona, Spain – September 2013).- The Spanish biotech company AB-Biotics announced that the European Patent Office (EPO) has granted a patent which protects the composition of its cholesterol-lowering probiotic AB-Life.
  View more
5 September 2013
Algenex increases production of raw material to supply Boehringer Ingelheim Vetmedica (BIV) ALGENEX (Alternative Gene Expression S.L.)
ALGENEX is proud to announce that it is increasing its production in Madrid to support its licensee, Boehringer Ingelheim Vetmedica (BIV), with sufficient virus recombinant antigens, a key raw material for use in SVANOVIR® ASFV-Ab, a kit for the serological diagnosis of African Swine Fever.
  View more
2 September 2013
ALGENEX creates the position of Head of Global Business Development ALGENEX (Alternative Gene Expression S.L.)
As part of its corporate strategy to supply its Top-Bac® and IBES® technology directly to the high quality protein market, ALGENEX, has created the position of Head of Global Business Development
  View more
26 July 2013
AB-Biotics gets patent for iron solution AB-Fortis in China AB BIOTICS S.A.
Barcelona (Spain) July 26.- The Spanish biotech company AB-Biotics has been granted a patent by the China Patent & Trademark Office for the functional ingredient AB-Fortis, a patented encapsulated iron system that provides the recommended daily amount of iron in a single dose, while avoiding the metallic taste and classic side effects of standard iron supplements.
  View more
25 July 2013
SOM Biotech licenses a product for glioblastoma to Argon Pharma pharmaceuticals Parc Científic de Barcelona (PCB)
SOM Biotech licenses a product for glioblastoma to Argon Pharma pharmaceuticals
SOM Biotech, based at the Barcelona Science Park (PCB), has licensed to Argon Pharma, also located at the PCB, a new product with potential properties for the treatment of multiple glioblastoma, the most common malignant brain tumor. SOM0777 is an inhibitor of αvβ3 and αvβ5 integrins, proteins actively involved in the binding of cells to their environment.
  View more
18 July 2013
Oryzon obtains orphan designation for ORY-1001 for the treatment of Acute Myeloid Leukemia from the European Medicines Agency Oryzon Genomics S.A.
Barcelona, July 15th, 2013. Oryzon announced today that it has received from EMA the orphan designation for ORY-1001, an inhibitor of LSD1 for the treatment of Acute Myeloid Leukemia.
  View more
15 July 2013
Interview with Andrés Montefeltro n-life Therapeutics
Interview with Andrés Montefeltro n-life Therapeutics CEO describes his objectives and developments
  View more
9 July 2013
Frutarom and AB-Biotics Join to Promote an Encapsulated Iron AB BIOTICS S.A.
Frutarom Health, Switzerland, and the AB-Biotics biotech company, Spain, have signed an exclusive global Agency sale and marketing agreement (effective from July 1st 2013) for marketing AB-Fortis®, an encapsulated iron solution for the functional food market.
  View more
5 July 2013
Canvax Biotech inaugurates its new facilities in Scientific & Technological Park of Cordoba Canvax Biotech S.L.
Canvax Biotech inaugurates its new facilities in Scientific & Technological Park of Cordoba Our new facilities has a total area of 1,500 square meters, spread over three floors and first class equipments.
  View more
14 June 2013
Spanish Bank of Algae will work with Africa in search of genetic resources Banco Español de Algas
The Center negotiates access to Mozambique and Cape Verde genetic resources to create unique collections in the world. The BEA offer specialized training to countries of origin
  View more
13 June 2013
Mind the Byte announces first conference on cloud and science in the PCB Parc Científic de Barcelona (PCB)
Mind the Byte announces first conference on cloud and science in the PCB The first edition of “SciCloud: Scientific Cloud Annual Conference”, organized by Mind the Byte in collaboration with Amazon Web Services and the Parc Científic de Barcelona (PCB)has been held on June 12th in the PCB. The SciCloud conference, to be held annually, will bring together experts from different areas of cloud services and science to discover and exchange ideas and breakthroughs in this field.
  View more
7 June 2013
Era7 Bioinformatics publishes a new bacterial genome Era7 Information Technologies
Era7 Bioinformatics publishes a new bacterial genome We have published the first complete genome sequence of a Staphylococcus aureus strain assigned to clonal complex 12. Illumina sequencing data plus a little of PacBio data produces much better results than only Illumina.
  View more
4 June 2013
El test de cribado prenatal no invasivo TrisoNIM® amplía las prestaciones NIMGENETICS, GENÓMICA Y MEDICINA, SL
El test de cribado prenatal no invasivo TrisoNIM® amplía las prestaciones Además de detectar el síndrome de Down, Edwards y Patau, determina el sexo del bebé e informa de las aneuploidías de los cromosomas más comunes. TrisoNIM®es el único test de cribado prenatal no invasivo que se puede utilizar en embarazos gemelares y en receptoras de ovocitos.
  View more
3 June 2013
ilS selected for BioemprendedorXXI Insights in Life Sciences (ilS)
ilS selected for BioemprendedorXXI ilS is delighted to announce we have been selected for the BioemprendedorXXI programme
  View more
29 May 2013
SciCloud: Scientific Cloud annual conference Parc Científic de Barcelona (PCB)
SciCloud: Scientific Cloud annual conference The first edition of “SciCloud: Scientific Cloud Annual Conference”, organized by Mind the Byte in collaboration with Amazon Web Services and the Parc Científic de Barcelona (PCB)will be held on June 12th in the PCB. The SciCloud conference, to be held annually, will bring together experts from different areas of cloud services and science to discover and exchange ideas and breakthroughs in this field.
  View more
28 May 2013
IQS LIDERA UN CONSORCIO INTERNACIONAL EN REGENERACIÓN CARDÍACA CON RESULTADOS ALENTADORES CONTRA EL INFARTO DE MIOCARDIO, DIRIGIDO POR EL DR. CARLOS SEMINO IQS
IQS LIDERA UN CONSORCIO INTERNACIONAL EN REGENERACIÓN CARDÍACA CON RESULTADOS ALENTADORES CONTRA EL INFARTO DE MIOCARDIO, DIRIGIDO POR EL DR. CARLOS SEMINO Presentación del proyecto RECATABI de regeneración cardíaca a través de un implante bioactivo para el tratamiento de enfermos crónicos de infarto de miocardio, por el Dr. Carlos Semino, profesor asociado del Departamento de Bioingeniería IQS y director del Laboratorio de Ingeniería de Tejidos IQS, en consorcio con el Dr. Juan Carlos Chachques, del Hospital Georges Pompidou, París, y con el Dr. Antoni Bayés-Genís, de Can Ruti, Barcelona, entre otros.
Expertos internacionales en regeneración de tejidos como Meisel, de Halle, Alemania, Tiscornia, de la Universidad de Algarve, Portugal, Mata, de la Queen Mary University, Londres, M. Balcells, MIT/IQS, E. Montanya, IDIBELL, Bellvitge, J.M. García-Aznar, Universidad de Zaragoza, y S. Borrós, pusieron en común sus últimos avances en el simposio "Regenerative Medicine Today and Tomorrow".


  View more
24 May 2013
OncoNIM® CF Cáncer Familiar - Test genético para diagnóstico precoz de cáncer hereditario NIMGENETICS, GENÓMICA Y MEDICINA, SL
OncoNIM® CF Cáncer Familiar - Test genético para diagnóstico precoz de cáncer hereditario •Entre el 5% y 10% de los casos de cáncer son hereditarios. Los tumores hereditarios más prevalentes son el de mama, el colon y los tumores neuroendocrinos.
•La detección precoz es crucial para el tratamiento eficaz de la enfermedad.
•OncoNIM® CF Cáncer Familiar es un test genético que, en 10 días y con 10 ml de sangre, analiza el ADN completo de un paciente en busca de alteraciones que le confieran susceptibilidad de padecer cáncer.
  View more
19 May 2013
New article from Oh no sequences!, Era7 Bioinformatics' research group Era7 Information Technologies
New article from Oh no sequences!, Era7 Bioinformatics' research group A new article has been published: Genome Sequence of Klebsiella pneumoniae KpQ3, a DHA-1 β-Lactamase-Producing Nosocomial Isolate.
  View more
12 May 2013
New publication from our team in MBio: Bloody coli: a Gene Cocktail in Escherichia coli O104:H4 Era7 Information Technologies
New publication from our team in MBio: Bloody coli: a Gene Cocktail in Escherichia coli O104:H4 Our Research Director, Dr. Raquel Tobes has published an article in the mbio journal about Escherichia coli.
  View more
26 April 2013
Agrasys launches to the market the first newly created cereal for human consumption Parc Científic de Barcelona (PCB)
Agrasys launches to the market the first newly created cereal for human consumption Tritordeum is the result of the natural combination between durum wheat and a wild barley species native to Chile and Argentina, has accreditation as natural crop species, and has been developed with traditional breeding techniques at the Institute of Sustainable Agriculture (IAS) of the Spanish National Research Council (CSIC) in collaboration with the spin-off Agrasys, located at the Barcelona Science Park, which is now entering the market.
  View more
12 April 2013
Althia receives ENAC Accreditation for its technical competence and diagnostic laboratory in Pathology and Molecular Pathology ATRYS
The National Accreditation Body (ENAC) has granted accreditation to Althia Health, SL (Althia) in recognition of the quality and technical competence according to the criteria in the UNE-EN ISO 15189:2007, for testing of Pathology and Molecular Pathology.
  View more
10 April 2013
Secugen S.L. will participate on the National Congress of Human Genetics AEGH Secugen, S.L.
XXVII National Congress AEGH

Scientific Meeting:
Update on genetics of rare diseases

Thursday 11 april 2013
Schedule: 12:30h - 14:00h
Room Escudo
Hotel Meliá Castilla
Madrid
  View more
10 April 2013
Virtual Model of Novel Cancer Target Developed Plebiotic
Plebiotic confirms in silico the promising characteristics of a novel cancer target developed by UK based company Pharmacellion.
  View more
8 April 2013
Inveready and “la Caixa” invest in Minoryx Minoryx Therapeutics
1,5M€ commitment will advance the development of new treatments for life threatening rare diseases
  View more
2 April 2013
Día Mundial del Autismo Un test genético permite diagnosticar y tratar al niño precozmente NIMGENETICS, GENÓMICA Y MEDICINA, SL
•En España hay entre 300.000 y 350.000 personas autistas. Por cada 150 niños en edad escolar se diagnostica un caso de Trastorno del Espectro Autista (TEA).
•La detección precoz permite que los niños autistas pueden alcanzar cierta independencia en sus vidas.
•En 10 días y con solo una muestra de sangre, el test genético KaryoNIM® 180K Autismo realiza un análisis completo del ADN del paciente en busca de alteraciones que le confieran susceptibilidad de padecer un TEA.
  View more
2 April 2013
Inveready Biotech II makes an investment in Minoryx Therapeutics Inveready
Inveready Biotech II makes an investment in Minoryx Therapeutics
  View more
21 March 2013
AB-Biotics and GlaxoSmithKline sign an agreement to promote the test Neurofarmagen in Brazil AB BIOTICS S.A.
Barcelona (Spain), March 21st 2013.- GlaxoSmithKline (GSK) and the Spanish biotech company AB-Biotics, listed on the Spanish Alternative Stock Market (MAB), have reached an agreement by which GSK will handle the exclusive promotion of Neurofarmagen, the line of pharmacogenetic tests developed by AB-Biotics.
  View more
20 March 2013
Mind the Byte becomes an Amazon Web Services Technology Partner Parc Científic de Barcelona (PCB)
Mind the Byte becomes an Amazon Web Services Technology Partner The scientific-computational services company Mind the Byte –located at the Parc Científic de Barcelona– has gained Technology Partner status with Amazon Web Serveis (AWS) in order to offfer its clients cloud computing IT services on top of the AWS platform. The start up becomes the first technology partner of Amazon Web Services (AWS) in Spain, and the seventh around the world specializing in cloud solutions applied to bioinformatics and chemoinformatics.
  View more
20 March 2013
Integromics invests in the optimization of computing performance for bioinformatics applications Integromics, S.L.
Key collaboration with European experts of HPC to bring new big-data computing solutions into genomics
  View more
6 March 2013
AB-Biotics launches the first probiotic specifically designed against caries, gingivitis and halitosis AB BIOTICS S.A.
Barcelona (Spain), March.- The Spanish biotech company AB-Biotics, listed on the Spanish Alternative Stock Market (MAB), has launched the first probiotic specifically designed to fight the oral pathogens causing caries, gingivitis and halitosis or bad breath, very common oral health diseases which can affect up to 99% population.
  View more
5 March 2013
NIMGenetics, laboratorio español líder en diagnóstico genético, estará presente en BIO-Europe Spring® 2013, el principal encuentro biotecnológico de partnering en Europa NIMGENETICS, GENÓMICA Y MEDICINA, SL
NIMGenetics, líder español en diagnóstico genético con aplicabilidad clínica, participará en BIO-Europe Spring® 2013, la edición de primavera del congreso de partnering de la industria biotecnológica y farmacéutica más importante en Europa, que se celebrará en Barcelona del 11 al 13 de marzo.
  View more
28 February 2013
Argon Pharma starts regulatory preclinical phase of an oral drug against pancreatic cancer Parc Científic de Barcelona (PCB)
Argon Pharma starts regulatory preclinical phase of an oral drug against pancreatic cancer
Oncostane – which has been proven to be effective in vivo– is one of the first oral treatments against pancreatic cáncer that reaches regulatory preclinical phase trials with an action mechanism completely different to that of drugs that are administered to fight the disease, which would make it a ‘first in class’ drug. The drug is also a wide spectrum drug exhibiting antitumor activity for several indications(reprofiling).
  View more
26 February 2013
GENOMICA AB starts its commercial activity GENOMICA
GENOMICA SAU climbs another step in its successful internationalization process by establishing, as the date of January 17th 2013, its Scandinavian subsidiary, GENOMICA AB.
Based in Lund (Sweden), AB GENOMICA intends to support the Scandinavian market (Denmark, Sweden and Norway), due to its strategic importance and also for its high growth potential.
  View more
25 February 2013
NIMGenetics firma con SECUVITA un acuerdo de comercialización de su test de cribado prenatal no invasivo TrisoNIM NIMGENETICS, GENÓMICA Y MEDICINA, SL
NIMGenetics firma con SECUVITA un acuerdo de comercialización de su test de cribado prenatal no invasivo TrisoNIM • Dos líderes en excelencia biomédica trabajarán conjuntamente en la difusión y oferta del test prenatal no invasivo a las futuras madres y a los ginecólogos.
• El acceso al test, un análisis de sangre, evitaría las más de 35.000 amniocentesis que se realizan en España cada año y que conllevan riesgos para la madre y el feto.
  View more
15 February 2013
IRBlleida researchers identify a molecular mechanism of one of the most aggressive breast cancers among young women Institut de Recerca Biomèdica de Lleida (IRBLleida)
IRBlleida researchers identify a molecular mechanism of one of the most aggressive breast cancers among young women Triple negative breast cancer has an incidence around 10-15% in young women. Is is known as the most lethal cancer because there are no currently effective treatments.
  View more
11 February 2013
Quiron Hospital of Valencia and Sistemas Genómicos will work together in the early diagnosis of melanoma. Sistemas Genómicos (Grupo ASCIRES)
Quiron Hospital of Valencia will offer their patients an innovative test for early diagnosis of melanoma, "MRisk" , which determines the susceptibility of developing a melanoma by joint measurement of genetic risk, phenotypic risk and exogenous factors.
  View more
5 February 2013
ABILITY PHARMACEUTICALS awarded a 1.2 million euros grant to develop its Lipid Analog ABTL0812 for Lung and Pancreatic Cancer Ability Pharmaceuticals, SL
The grant will fund the first-in-man phase Ib clinical trial in advanced cancer patients with refractory solid tumor
The program will be presented at the 2013 ASCO Meeting and involves the Autonomous University of Barcelona and the research institute IDIBAPS
  View more
1 February 2013
Our clients are our guarantee Sistemas Genómicos (Grupo ASCIRES)
"High-Throughput Sequencing of microRNAs in Peripheral Blood Mononuclear Cells: Identification of Potential Weight Loss Biomarkers"
  View more
29 January 2013
Diagnostics Biomedal increases sales by more than 50% Biomedal, S.L.
Biomedal Diagnostics, the Biomedal SL division specialized in human health, has increased its sales by over 50% in 2012 over the previous year, despite the current economic climate
  View more
29 January 2013
Rafael Camacho, exGeneral Director of the Genome Spain Foundation, new Innovation Advisor at Sistemas Genomicos. Sistemas Genómicos (Grupo ASCIRES)
Rafael Camacho, exGeneral Director of the Genome Spain Foundation, new Innovation Advisor at Sistemas Genomicos. Sistemas Genomicos announces the hiring, as Innovation Advisor, of one of the most outstanding national experts in the field of biomedical research and innovation management. Rafael Camacho Fumanal, who in the last three years has led the Genome Spain Foundation
  View more
22 January 2013
IQS Y PANGAEA BIOTECH AÚNAN ESFUERZOS IQS
IQS Y PANGAEA BIOTECH AÚNAN ESFUERZOS IQS y Pangaea Biotech, SL, firman un convenio a tres años para emplear moléculas sintetizadas por el Grup d'Enginyeria Molecular de IQS con el objetivo de establecer nuevos tratamientos y nuevos fármacos contra el cáncer de pulmón y otros tipos de tumores sólidos.
  View more
17 January 2013
Enzymlogic honored with the Science Park of Madrid Foundation Award Enzymlogic
Enzymlogic honored with the Science Park of Madrid Foundation Award Enzymlogic received the Science Park of Madrid Foundation Award for The Best Scientific Project, which recognizes technological projects that put innovation at the heart of their business strategy and have high-growth potential.
  View more
2 January 2013
BIOTOOLS, quality solutions for the biomedical sector Biotools B&M Labs, S.A.
BIOTOOLS, quality solutions for the biomedical sector En nuestra cartera de productos podemos encontrar kits de biología molecular para investigación, diagnóstico de enfermedades virales e infecciosas y de identificación de especies animales, entre otros.
  View more
21 December 2012
Bionaturis to tackle the vaccination system for fish farming with oral vaccines BIONATURIS GROUP
Bionaturis to tackle the vaccination system for fish farming with oral vaccines ? The AQUAFLY project, based on the Bionaturis FLYLIFE production system, will be deployed in collaboration with the Department of Chemical Engineering, Food Technology and Environmental Sciences, at the Science Faculty of Cadiz University; and CTAQUA (Andalusian Aquaculture Technological Centre Foundation).
  View more
17 December 2012
AB-Biotics closes €5-millions round of funding AB BIOTICS S.A.
Barcelona, 17th December 2012.- Spanish biotechnology firm AB-Biotics, which is
traded on the Alternative Stock Market (MAB), has met their goal of closing a round of
funding for €5 millions before the end of 2012.
  View more
12 December 2012
Althia boosts its R&D area with Augusto Silva ATRYS
Althia boosts its R&D area with Augusto Silva Dr. Augusto Silva has joined Althia’s scientific team as head of R&D. His signing shows the company's commitment to research excellence in the field of Oncology.
  View more
6 December 2012
In New England Cable News (NECN) Era7 Bioinformatics gets mentioned Era7 Information Technologies
In New England Cable News (NECN) Era7 Bioinformatics gets mentioned In New England Cable News (NECN) on Fri, 30 Nov 2012, VP of the Mass. Life Sciences Center talks about new companies in the Bay State and Era7 Bioinformatics gets mentioned
  View more
5 December 2012
AB-Biotics launches a new food ingredient which prevents iron deficiency AB BIOTICS S.A.
Barcelona, Spain, 5/12/12.- The Spanish biotech company AB-Biotics has launched a new food ingredient, called AB-Fortis, which prevents iron deficiency.
  View more
4 December 2012
Iproteos wins the 2nd prized at RedEmprendia - Spin 2012 IPROTEOS
Iproteos has been awarded the second prize at the first edition of the RedEmprendia University to Business Competition. The award, set at 15,000 euros and sponsored by NH Hotels, was presented last November 28th during the ‘RedEmprendia Spin2012’ conference held in Madrid.
  View more
4 December 2012
Últimos avances en genética de demencias y esclerosis lateral amiotrófica Secugen, S.L.
SECUGEN patrocina la reunión científico docente: Actualización en Genética de Demencias y ELA en la LXIV Reunión Anual de la Sociedad Española de Neurología celebrada en Barcelona
  View more
30 November 2012
PHARMAMAR Y ORYZON colaboran en la identificación de marcadores clínicos Pharmamar, S.A.
PHARMAMAR Y ORYZON colaboran en la identificación de marcadores clínicos PharmaMar ha iniciado una colaboración con Oryzon con el objeto de identificar marcadores clínicos en sus diferentes productos antitumorales.
  View more
29 November 2012
Era7 Bioinformatics expands to U.S., Opens office in Cambridge, Mass. Era7 Information Technologies
Era7 Bioinformatics expands to U.S., Opens office in Cambridge, Mass. CAMBRIDGE, Mass. – Nov. 29, 2012 – Era7 Bioinformatics, a Next Generation Sequencing provider based in Spain, announced today the opening of its first U.S. office, located in the Cambridge Innovation Center (CIC) in Cambridge, Massachusetts. Era7 expects to have three employees in Cambridge by the end of 2013.
  View more
29 November 2012
BG7, the Open Source Bacterial Genome annotation system from Era7 Bioinformatics gets published in PLOS ONE Era7 Information Technologies
BG7, the Open Source Bacterial Genome annotation system from Era7 Bioinformatics gets published in PLOS ONE BG7 bacterial genome annotation system from Era7 Bioinformatics is specially designed for Next Generation Sequencing data.
  View more
26 November 2012
Expertos nacionales analizan las principales herramientas para valorar y transferir las buenas ideas en biomedicina FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD
La Oficina de Transferencia de Tecnología del Sistema Sanitario Público de Andalucía (OTT-SSPA) ha organizado un curso destinado a los profesionales que deseen adquirir competencias en la valorización de intangibles en I+D+i
  View more
15 November 2012
Althia increases its equity by 3 million euros ATRYS
Althia increases its equity by 3 million euros Madrid, October 30, 2012. - Althia, the biomedical company focused on personalized predictive oncology, has increased its equity by 3 million euros, due to the entry of two new investors in the shareholding of the company.
Reiman, Inveready and Investment Group, SL are two business groups specialized in the health sector.
  View more
7 November 2012
AB-Biotics signs agreement with HanAll BioPharma to distribute its cholesterol-lowering probiotic in Korea AB BIOTICS S.A.
Barcelona (Spain), November, 2012 - The Spanish biotech company AB-BIOTICS has signed a 10-year license agreement which gives HanAll BioPharma exclusive rights to distribute its cholesterol-lowering probiotic AB-LIFE in South-Korea.
  View more
26 October 2012
BioCloud will develop a pioneer project on inflammatory neurodegenerative diseases Parc Científic de Barcelona (PCB)
The BioCloud Research Consortium –an Economic Interest Group (EIG), formed by four companies based at the Barcelona Science Park –Intelligent Pharma, Neurotec Pharma, PaloBiofarma and SOM Biotech– has received a 300,000€ grant through ACC1Ó´s Technological Innovation Clusters programme and co-funding from the European Regional Development Fund (ERDF).
  View more
23 October 2012
Almirall invests in AB-Biotics to strengthen the pharmacogenetics area AB BIOTICS S.A.
Barcelona, 23 October 2012.- Almirall (ALM.MC), the international pharmaceutical company headquarted in Barcelona, has reached an agreement with the Spanish biotech company AB-Biotics (ABB.MC) to enter the share capital of the company listed on the Spanish Alternative Investment Market (MAB).
  View more
19 October 2012
AB-BIOTICS llega a México con un contrato de licencia para su probiótico anti-colesterol AB BIOTICS S.A.
AB-BIOTICS llega a México con un contrato de licencia para su probiótico anti-colesterol El contrato supondrá un volumen de negocio de unos 2,3 millones de euros para AB-BIOTICS en los próximos tres años
  View more
19 October 2012
Merck Serono and Auxogyn Announce Partnership in Test Eeva ™ Merck S.L.
Merck Serono and Auxogyn Announce Partnership in Test Eeva ™ The Feasibility Assessment Test early embryo (Test Eeva ™) is designed to provide data to help assess embryo viability.
This strategic partnership demonstrates the strong commitment of Merck Serono to continue investing in assisted reproductive technologies.
  View more
19 October 2012
New public-private open innovation project for the repositioning of 20 drugs Parc Científic de Barcelona (PCB)
New public-private open innovation project for the repositioning of 20 drugs A public-private open innovation project to discover new drugs based on repurposing (repositioning)- the result of a collaboration agreement between the Drug Discovery Platform (DDP) at the Barcelona Science Park (PCB) and the companies SOM Biotech and Metasbio, both located at the PCB, has obtained a grant of 441,884 Euros from the Genome Spain Foundation through the Innocash credit line.
  View more
19 October 2012
Muscletech Network Congress, closer to the end of muscle injuries Centro Tecnológico LEITAT
Muscletech Network Congress, closer to the end of muscle injuries In the 4th Congressional MuscleTech Network, international experts discussed the latest results on the diagnosis and recovery from muscle injuries that will affect the performance of both professional and amateur athletes.
  View more
19 October 2012
ORYZON and CANCER RESEARCH UK’S Paterson Institute for Cancer Research have started a collaborative research project on therapeutic uses of LSD1 inhibitors for Acute Leukaemia Oryzon Genomics S.A.
ORYZON and CANCER RESEARCH UK’S Paterson Institute for Cancer Research have started a collaborative research project on therapeutic uses of LSD1 inhibitors for Acute Leukaemia The Cancer Research UK-funded research is led by Dr Tim Somervaille, Group Leader of the Cancer Research UK Leukaemia Biology group at the Paterson Institute for Cancer Research and Honorary Consultant in Haematology at The Christie NHS Foundation Trust in Manchester (UK).
The collaboration is focused to achieve a deeper understanding of the inhibition of histone lysine demethylation as a stopper mechanism for onset and progression of acute leukaemia.
  View more
18 October 2012
Ferran Prat, nombrado Vicepresidente de Operaciones para la división de Medicina Personalizada de Vivia Biotech Vivia Biotech, S.L.
Ferran Prat, nombrado Vicepresidente de Operaciones para la división de Medicina Personalizada de Vivia Biotech La empresa española de biotecnología Vivia Biotech acaba de nombrar a Ferran Prat Vicepresidente de Operaciones de la compañía para liderar la comercialización y estrategia de la división de Medicina Personalizada.
  View more
16 October 2012
Bionaturis joins the “Targetfish” project BIONATURIS GROUP
Bionaturis joins the “Targetfish” project This project mainly seeks to develop new vaccines for aquaculture, with a focus on the species and fighting against the diseases with the greatest economic impact in the European Union.
  View more
24 September 2012
SALUD LLEVA SU ESTRATEGIA EN INVESTIGACIÓN BIOMÉDICA AL 6º ENCUENTRO INTERNACIONAL DE BIOTECNOLOGÍA, BIOSPAIN 2012 FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD
Representantes de la Iniciativa Andaluza en Terapias Avanzadas, la Oficina de Transferencia de Tecnología, el Biobanco del SSPA y los centros de investigación temáticos han estado presentes en la feria celebrada en Bilbao
  View more
21 September 2012
AB-Therapeutics closes 1 million euro financing round and changes the company name to Ability Pharmaceuticals Ability Pharmaceuticals, SL
The Catalan Biopharmaceutical company will use the new funds in the clinical development of its novel anticancer drug in lung and pancreatic cancer.
Inveready Seed Capital, Genoma España, shareholders, business angels and private investors participate in the funding.
  View more
19 September 2012
“Biotools es ya una veterana en la fabricación de productos biotecnológicos” Biotools B&M Labs, S.A.
“Biotools es ya una veterana en la fabricación de productos biotecnológicos”
“Biotools es ya una veterana en la fabricación de productos biotecnológicos”

Fundada en 1996, Biotools es una empresa biotecnológica española con presencia global, creada con la misión de desarrollar soluciones de calidad para clientes del sector biomédico,
biotecnológico y de ciencias de la vida.

ENTREVISTA
Isabel Jiménez González Directora de Marketing y Ventas de Biotools
“Trabajamos en la
aplicación de tecnología
propia, como la tecnología
LionProbes® y la de Gelicación”
  View more
6 September 2012
Salud firma un acuerdo de licencia para la explotación de los resultados de un ensayo clínico en terapia celular FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD
La empresa biofarmacéutica Innovaxis apoyará la realización de la fase III de este estudio sobre pie diabético liderado por el Hospital Reina Sofía de Córdoba
  View more
20 August 2012
With our technology, drugs would reach the market 20% earlier Plebiotic
The press release describes how drugs could be developed much faster and with a far lower cost by using the design and screening tool created by Plebiotic
  View more
19 July 2012
Plebiotic, spanish software for drug design Plebiotic
Plebiotic has developed a biomedical software with revolutionary applications for medical investigation
  View more
16 June 2012
SALUD LLEVA A ESTADOS UNIDOS SU MODELO DE TRANSFERENCIA DE TECNOLOGÍA Y PROMOCIÓN DE LA I+D+i FUNDACIÓN PÚBLICA ANDALUZA PROGRESO Y SALUD
La Oficina de Transferencia de Tecnología de la sanidad andaluza estará presente en la mayor cita internacional del sector biotecnológico que se celebra entre el 18 y el 21 de junio en la ciudad americana de Boston
  View more
7 May 2012
Oryzon presents its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston Oryzon Genomics S.A.
Oryzon presents its LSD1 program in Acute Leukemias at the GTC’s 2nd Epigenetics in Drug Discovery conference in Boston Oryzon announced today that Dr. Tamara Maes will present the latest advances of its LSD1 program in hematological malignancies at GTC’s 2nd Epigenetics in Drug Discovery conference in the session Drug Discovery in Epigenetics: on May 30-31 at the Hyatt Harborside in Boston, MA.
  View more
2 May 2012
AB-BIOTICS desembarca en Sudamérica con dos contratos de licencia para Brasil y Venezuela AB BIOTICS S.A.
AB-BIOTICS desembarca en Sudamérica con dos contratos de licencia para Brasil y Venezuela La biotech española cotizada en el MAB firma un acuerdo con BIOLAB, el segundo mayor laboratorio de capital brasileño, para la distribución de su probiótico AB-LIFE en Brasil.
  View more
16 April 2012
La empresa española Vivia Biotech cierra su segunda ronda de financiación por 7,2 millones € Vivia Biotech, S.L.
La empresa española Vivia Biotech cierra su segunda ronda de financiación por 7,2 millones € La empresa está centrada en el desarrollo de fármacos y medicina personalizada en cáncer hematológico
La ronda financiará la llegada al mercado de los test de medicina personalizada de Vivia Biotech
Además de Europa, donde la empresa comercializará sus test, Vivia estima una rápida expansión a EEUU, Latinoamérica y al mercado asiático vía licencia.
  View more
12 April 2012
Drugs from ORYZON shown to be efficacious in the treatment of Acute Leukemia Oryzon Genomics S.A.
Drugs from ORYZON shown to be efficacious in the treatment of Acute Leukemia According to promising preclinical results published in Nature Medicine and Cancer Cell.
  View more
10 April 2012
Web4bio releases the new version of DoPlanning Era7 Information Technologies
The new version of Web4bio’s flagship productivity tool, developed by Era7, includes a number of new features, mostly based on suggestions from users.
  View more
29 March 2012
Gradocell opens in monitoring clinical trials GRADOCELL,SL
Gradocell after a year and eight months working as a consultant specializing in Advanced Therapies, opens a new line of business focused on the monitoring and control of clinical trials for Advanced Therapies.
  View more
14 March 2012
Spanish Research Team Uses Roche's GS FLX+ System to Sequence Antibiotic Resistance Bacteria in Recent Hospital Outbreak Era7 Information Technologies
Spanish Research Team Uses Roche's GS FLX+ System to Sequence Antibiotic Resistance Bacteria in Recent Hospital Outbreak A team of researchers from the Hospital Universitario La Paz Research Institute (IdiPAZ, Madrid), LifeSequencing S.L. (Valencia), Era7 Bioinformatics (Madrid) and Roche Spain (Barcelona) announced today the sequencing of the whole genome of three antibiotic resistant strains of Klebsiella pneunomiae isolated from a recent outbreak in a Spanish hospital.
  View more
19 February 2012
Oryzon participates in a R&D European consortium in Parkinson’s disease Oryzon Genomics S.A.
Oryzon participates in a R&D European consortium in Parkinson’s disease Oryzon a Biopharmaceutical company dedicated to the discovery of biomarkers and development of novel therapeutics and diagnostics announced that its CSO, Dr. Tamara Maes, participated at the kick-off meeting of the European Porject DDPDGENES held on January 16 and 17 in Stockholm (Sweden).
  View more
15 February 2012
BG7 is selected by Pacific Biosciences as partner product Era7 Information Technologies
BG7 is selected by Pacific Biosciences as partner product Complete BG7, our bacterial genome annotation system, has been selected by Pacific Biosciences to be included in their partner products: http://www.pacificbiosciences.com/partner_products/
  View more
9 February 2012
Integromics se asocia con FPGMX para desarrollar métodos de análisis de bajo coste en el campo de la genómica clínica Integromics, S.L.
Integromics se asocia con FPGMX para desarrollar métodos de análisis de bajo coste en el campo de la genómica clínica Esta iniciativa atrae a 1 millón de euros de financiación para superar la "nueva frontera" de la interpretación de datos para uso médico
  View more
7 February 2012
Oryzon inicia el desarrollo preclínico de su primer fármaco candidato para eltratamiento de la enfermedad de Huntington Oryzon Genomics S.A.
En modelos animales ha demostrado que aumenta la supervivencia y mejora diversos trastornos motores y de comportamiento.
  View more
26 January 2012
Bionaturis da la campanada BIONATURIS GROUP
Bionaturis da la campanada La empresa andaluza de biotecnología se incorpora al MAB
  View more
26 January 2012
Oryzon presentará sus avances en el 4º CHI X-Gen Congreso Anual en Epigenética, Dianas y Terapias Oryzon Genomics S.A.
Oryzon presentará sus avances en el 4º CHI X-Gen Congreso Anual en Epigenética, Dianas y Terapias La compañía biofarmacéutica, dedicada al descubrimiento de biomarcadores y al desarrollo de nuevas terapias y diagnósticos, ha anunciado que la Dra. Tamara Maes, directora científica de Oryzon, presentará los últimos avances realizados en este campo en el IV congreso anual de X-GEN del CHI, concretamente en la sección de Genómica Clínica, Epigenética, Dianas y Terapias, del 5 al 7 de marzo en el Hotel Hilton de San Diego (California, Estados Unidos)
  View more
25 January 2012
Un nuevo test genético identifica el tratamiento más efectivo para cada paciente con depresión a partir de su saliva AB BIOTICS S.A.
Un nuevo test genético identifica el tratamiento más efectivo para cada paciente con depresión a partir de su saliva El análisis, llamado Neurofarmagen Depresión, ha sido desarrollado por la biotecnológica española AB-BIOTICS.
  View more
16 September 2011
Oryzon lanzará su primer producto al mercado: un test no invasivo para la detección del cáncer de endometrio Oryzon Genomics S.A.
Oryzon lanzará su primer producto al mercado: un test no invasivo para la detección del cáncer de endometrio Permite realizar un diagnóstico ambulatorio a partir de una muestra de aspirado uterino, evitando así la necesidad de histeroscopias en las pacientes.
  View more
9 September 2011
3P Biopharmaceuticals estudia su implantación en EEUU 3P Biopharmaceuticals, S.L.
3P Biopharmaceuticals estudia su implantación en EEUU La compañía participa en Boston en un programa orientado a facilitar el despliegue de su actividad en el mercado estadounidense.
  View more
1 September 2011
Biomar Microbial Technologies incrementará su facturación a través de un plan de internacionalización y diversificación BIOMAR Microbial Technologies, S.A.
Biomar Microbial Technologies incrementará su facturación a través de un plan de internacionalización y diversificación Obtiene buenos resultados en sus investigaciones para tratar el Glioblastoma y la esclerosis múltiple
  View more
31 August 2011
AB-BIOTICS pone en marcha su plan de expansión internacional en Estados Unidos, Europa y América Latina AB BIOTICS S.A.
AB-BIOTICS pone en marcha su plan de expansión internacional en Estados Unidos, Europa y América Latina El objetivo es comercializar sus soluciones de medicina personalizada en países como EE.UU., Reino Unido, Alemania, Francia, Turquía, México y Brasil.
  View more
15 June 2011
Era7 adds Genomica SAU’s corporate website to its web & multimedia portfolio Era7 Information Technologies
Era7 adds Genomica SAU’s corporate website to its web & multimedia portfolio A new environment, more modern and in line with the image of other companies from Zeltia characterizes the new corporate website of Genomica SAU (link a http://www.genomica.es/en/index.cfm), developed entirely by Era7 and its Web & Multimedia Division.
  View more
10 June 2011
New open call - marketing course on social networks for biotechnology Era7 Information Technologies
New open call - marketing course on social networks for biotechnology At Era7 we put our experience in Social Media Marketing to service the biotechnology sector, with a course we teach on a regular basis at our offices in Madrid.
  View more
9 June 2011
A spanish project for protein folding simulation Plebiotic
A spanish project for protein folding simulation
  View more
3 June 2011
Era7 bioinformatics company makes one of the first functional genome annotations of the Escherichia coli bacteria at the centre of the German outbreak. Era7 Information Technologies
Era7 bioinformatics company makes one of the first functional genome annotations of the Escherichia coli bacteria at the centre of the German outbreak. After the publication by the Chinese genomics center BGI of a preliminary version of the DNA sequence of the E. coli bacteria, which has probably caused the European outbreak starting in Germany, Era7 achieves in less than 24 hours a first functional annotation based on the preliminary assembly by the English scientist Nick Loman.
  View more
9 May 2011
AB-BIOTICS lanza la nueva versión de Neurofarmagen® con 39 principios activos analizados AB BIOTICS S.A.
AB-BIOTICS lanza la nueva versión de Neurofarmagen® con 39 principios activos analizados El análisis predice la respuesta del paciente a los fármacos más usados en Depresión, Esquizofrenia, Epilepsia y Trastorno Bipolar.
La nueva versión incorpora 4 nuevos principios activos: Pregabalina, Vigabatrina, Zucloplentixol y Mianserina
  View more
10 April 2011
NEIKER-Tecnalia obtiene almidón de alta calidad mediante nuevas herramientas de mejora genética en patata NEIKER - Instituto Vasco de Investigación y Desarrollo Agrario
NEIKER-Tecnalia obtiene almidón de alta calidad mediante nuevas herramientas de mejora genética en patata Neiker-Tecnalia, ha desarrollado un proyecto para la obtención de almidón de alta calidad, utilizando para ello nuevas herramientas de mejora genética en patata del género Solanum tuberosum. El objetivo de la investigación es lograr un almidón que presente las mejores condiciones fisicoquímicas para su uso industrial, así como almidón que permita producir alimentos más saludables y funcionales
  View more
21 March 2011
Los ingresos de AB-BIOTICS aumentan un 74% en 2010 hasta 3,58 millones de euros AB BIOTICS S.A.
Los ingresos de AB-BIOTICS aumentan un 74% en 2010 hasta 3,58 millones de euros La biotecnológica obtiene un beneficio neto de 17.658 euros, a pesar de que su plan de negocio preveía un escenario de pérdidas
  View more
14 March 2011
El Parque Científico de Madrid e Igen Biotech organizan un seminario sobre aptámeros Parque Científico de Madrid (PCM)
El seminario celebrado en el Parque Científico de Madrid, en colaboración con Igen Biotech, ha contado con más de ochenta asistentes, entre miembros de institutos de investigación, laboratorios farmacéuticos, empresas biotecnológicas y hospitales, interesados en conocer la tecnología y posibilidades futuras de los aptámeros.
  View more
3 March 2011
Genoma España y Suanfarma Biotech se unen para incrementar y optimizar las inversiones en biotecnología FUNDACION ESPAÑOLA PARA LA CIENCIA Y LA TECNOLOGIA
Genoma España y Suanfarma Biotech se unen para incrementar y optimizar las inversiones en biotecnología - Genoma España y Suanfarma han firmado hoy un acuerdo de colaboración para maximizar las oportunidades de promoción y éxito de proyectos biotecnológicos españoles.
- La biotecnología uno de los pilares para avanzar hacia el cambio de modelo económico.
  View more
25 February 2011
TiGenix anuncia su fusión con Cellerix y propone una ampliación de capital mediante una oferta pública de acciones TIGENIX SAU
TiGenix anuncia su fusión con Cellerix y propone una ampliación de capital mediante una oferta pública de acciones La combinación de estas compañías creará un líder europeo en terapia celular con dos medicamentos en el mercado y una prometedora cartera de productos en desarrollo para indicaciones con un gran mercado potencial
  View more
9 February 2011
Veterindustria y la Asociación de Hospitales Veterinarios Universitarios de España (AHVUE) firman un convenio de colaboración Veterindustria
Veterindustria y la Asociación de Hospitales Veterinarios Universitarios de España (AHVUE) firman un convenio de colaboración Ambas instituciones se comprometen a colaborar en campos como la investigación y el desarrollo, y la formación de los futuros profesionales
  View more
7 February 2011
El ministro de Educación visita el Parc Científic de la Universidad de Barcelona Parc Científic de Barcelona (PCB)
El ministro de Educación visita el Parc Científic de la Universidad de Barcelona El ministro ha conocido los programas de formación que se están llevando a cabo para acercar el entorno de la investigación a los estudiantes universitarios.

El Parc Científic Barcelona culminó este año su ampliación hasta 60.000 m2 y fue el primero creado en España. Forma parte de Barcelona Knowledge Campus, proyecto seleccionado en 2009 como “Campus de Excelencia Internacional”
  View more
31 January 2011
Añadir Erbitux a la quimioterapia estándar con FOLFOX produce un beneficio en la supervivencia a largo plazo en pacientes con cáncer colorrectal metastático y KRAS nativo Merck S.L.
Añadir Erbitux a la quimioterapia estándar con FOLFOX produce un beneficio en la supervivencia a largo plazo en pacientes con cáncer colorrectal metastático y KRAS nativo • La reducción temprana del tamaño del tumor lograda con Erbitux más FOLFOX se asocia a una mayor supervivencia a largo plazo (una mediana de supervivencia global de 26.2 meses) en pacientes con cáncer colorrectal metastásico y KRAS nativo.

• El estudio aleatorizado CORE.1.2.002 confirma una alta tasa de respuesta (63%) con la combinación Erbitux-FOLFOX administrando dicho tratamiento cada dos semanas.
  View more
31 January 2011
La Oficina Europea de Patentes da luz verde a un ingrediente funcional que reduce el colesterol en un 14% AB BIOTICS S.A.
La Oficina Europea de Patentes da luz verde a un ingrediente funcional que reduce el colesterol en un 14% Los examinadores internacionales avalan AB-LIFE, de la biotecnológica española AB-BIOTICS

Se trata del primer probiótico con efectos cardiovasculares y su eficacia ha sido probada en estudios clínicos del Hospital Puerta del Hierro de Madrid
  View more
24 January 2011
Ampliación de capital de Owl Genomics One Way Liver, SL. (OWL)
Ampliación de capital de Owl Genomics Owl Genomics, acaba de cerrar con éxito una ampliación de capital de 2 MM de euros, dando entrada a inversores privados del País Vasco y México así como a la Sociedad de Capital Riesgo del País Vasco y la Fundación Clinic de Barcelona.
  View more
19 January 2011
El Parque Científico de Madrid acoge la presentación de la Plataforma Quoolife Parque Científico de Madrid (PCM)
El Parque Científico de Madrid acoge la presentación de la Plataforma Quoolife La empresa Bet Quality of Life ha desarrollado una innovadora Plataforma, Qoolife, una red social de confianza destinada a prestar soluciones tanto a pacientes crónicos, personas dependientes y familiares, como a profesionales sanitarios.
  View more
18 January 2011
Vivia Biotech presenta su test de Medicina Personalizada en Silicon Valley Vivia Biotech, S.L.
Vivia Biotech presenta su test de Medicina Personalizada en Silicon Valley • Es la única representante española en la III Conferencia Mundial de Medicina Personalizada (PMWC 2011) de Silicon Valley, California.
• El jurado del evento seleccionó 20 empresas para presentar sus proyectos, Vivia y una empresa israelí eran las únicas no americanas.
• El encuentro internacional es una de las citas más importantes del mundo de biotecnología en el campo de medicina personalizada.
  View more
18 January 2011
AB-Biotics solicita la patente de uso de un producto capaz de reducir un 38% los niveles de glucosa en sangre tras las comidas AB BIOTICS S.A.
AB-Biotics solicita la patente de uso de un producto capaz de reducir un 38% los niveles de glucosa en sangre tras las comidas La biotecnológica descubre una nueva aplicación para las sales magnésicas de ácidos grasos, hasta ahora utilizadas como emulsionante alimentario.

Podría administrarse como medicamento o incluirse en la preparación de un producto alimenticio o suplemento dietético.
  View more
17 January 2011
NEIKER-tecnalia apuesta nuevamente por la calidad de sus servicios analíticos al ampliar el alcance de sus acreditaciones NEIKER - Instituto Vasco de Investigación y Desarrollo Agrario
NEIKER-tecnalia apuesta nuevamente por la calidad de sus servicios analíticos al ampliar el alcance de sus acreditaciones La Comisión de Acreditación de ENAC acaba de conceder a los laboratorios de NEIKER-tecnalia la ampliación de su alcance de acreditación.
  View more
17 January 2011
La nueva directora de la AEMPS se reúne con Veterindustria Veterindustria
La nueva directora de la AEMPS se reúne con Veterindustria La labor desarrollada por Veterindustria y la estrecha colaboración mantenida hasta el momento con la Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), centraron los temas a tratar en esta primera reunión con la nueva directora.
  View more
11 January 2011
MSD adquiere SmartCells, Inc. Merck, Sharp & Dohme de España, S.A. (MSD)
MSD adquiere SmartCells, Inc. MSD (denominada Merck & Co Inc en USA) y SmartCells Inc., anunciaron la firma de un acuerdo definitivo por el que la compañía farmacéutica adquiere SmartCells, una empresa privada que desarrolla una formulación de insulina sensible a la glucosa para el tratamiento de la diabetes mellitus.
  View more
11 January 2011
AB Therapeutics incorpora a José Alfón como Director de Desarrollo AB BIOTICS S.A.
AB Therapeutics incorpora a José Alfón como Director de Desarrollo La compañía catalana AB Therapeutics, filial independiente de AB-Biotics focalizada en el desarrollo de nuevos fármacos, acaba de incorporar a José Alfón Coriat, hasta ahora Líder de Proyecto en Palau Pharma, como Director de Desarrollo de la compañía
  View more
10 January 2011
Oryzon recibe 300.000 dólares de la Alzheimer's Drug Discovery Foundation Oryzon Genomics S.A.
Oryzon recibe 300.000 dólares de la Alzheimer's Drug Discovery Foundation Con ello, la biotecnológica se convierte en la primera empresa española en recibir un grant de esta entidad benéfica y en colaborar con ella
  View more
3 January 2011
Merck Serono y Philochem llegan a un acuerdo de investigación en fertilidad Merck S.L.
Merck Serono y Philochem llegan a un acuerdo de investigación en fertilidad Merck Serono, la división biotecnológica de la compañía químico farmacéutica alemana Merck ha anunciado un acuerdo estratégico con la compañía suiza Philochem AG, unidad de investigación de Philogen S.p.A., con sede en Italia. Según los términos de dicho acuerdo, Philochem suministrará anticuerpos monoclonales específicos a Merck Serono, destinados a la búsqueda de biomarcadores moleculares capaces de determinar la calidad embrionaria y ovocitaria.
  View more
3 January 2011
Merck Serono y Philochem llegan a un acuerdo de investigación en fertilidad Merck S.L.
Merck Serono y Philochem llegan a un acuerdo de investigación en fertilidad Merck Serono, la división biotecnológica de la compañía químico farmacéutica alemana Merck ha anunciado un acuerdo estratégico con la compañía suiza Philochem AG, unidad de investigación de Philogen S.p.A., con sede en Italia. Según los términos de dicho acuerdo, Philochem suministrará anticuerpos monoclonales específicos a Merck Serono, destinados a la búsqueda de biomarcadores moleculares capaces de determinar la calidad embrionaria y ovocitaria.
  View more
13 December 2010
AB-BIOTICS firma un acuerdo con Laboratorios Rubió para la distribución en España de Neurofarmagen TDAH® AB BIOTICS S.A.
AB-BIOTICS firma un acuerdo con Laboratorios Rubió para la distribución en España de Neurofarmagen TDAH® •Este análisis genético permite conocer la respuesta del paciente a los principales fármacos para el trastorno por déficit de atención con hiperactividad, y ayuda a valorar el riesgo de desarrollarlo en el futuro
•El TDAH es una de las alteraciones de la conducta más comunes, con una prevalencia mundial en torno al 5% en niños y el 3% en adultos
•El contrato supondrá para AB-BIOTICS un volumen de negocio mínimo de 1,5 millones para el periodo 2011-2013
  View more
9 December 2010
AB-BIOTICS investiga con J.Vigas, Cavas Hill y Bigas Alsina un método para eliminar el “sabor a corcho” en vinos y cavas AB BIOTICS S.A.
AB-BIOTICS investiga con J.Vigas, Cavas Hill y Bigas Alsina un método para eliminar el “sabor a corcho” en vinos y cavas •Aunque popularmente se le conoce con este nombre incorrecto, la causa no está en el corcho sino en el TCA (tricloroanisol), que tiene su origen en biocidas sintéticos
•Al estar presente en el ambiente, este compuesto volátil es susceptible de ser absorbido por el corcho y pasar al líquido
•El proyecto supone una inversión de 1,5 millones de euros y cuenta con financiación del CDTI y el Fondo Tecnológico (FEDER)
  View more
30 November 2010
Vivia Biotech, galardonada con dos premios de Innovación en Castilla y León Vivia Biotech, S.L.
Vivia Biotech, galardonada con dos premios de Innovación en Castilla y León •La empresa de biotecnología Vivia Biotech recibe hoy el galardón Mejor Innovación en Calidad de Vida en los I Premios Innovadores Valladolid 2010 por la búsqueda de calidad de vida para los pacientes.
•Asimismo ha recibido el premio al Producto Más Innovador en los IV Premios Castilla y León Económica Foro Burgos por su plataforma tecnológica pionera en el mundo, ExVitech©.
  View more
10 November 2010
Oryzon Licenses Human Antibody Phage Display Technology for Discovery of Novel Therapeutics From Dyax Corp. Oryzon Genomics S.A.
Oryzon Licenses Human Antibody Phage Display Technology for Discovery of Novel Therapeutics From Dyax Corp. Barcelona (Spain), 10.11.2010. Oryzon announced today that it has signed a non-exclusive license with Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, to develop therapeutic antibody products using Dyax’s proprietary technology, phage display. This Agreement grants Oryzon a non-exclusive license to use Dyax’s human antibody libraries to discover antibodies and the right to commercially develop such antibody products.
  View more
Developed by Web4Bio